EP2990795B1 - Rare particle detection method and apparatus - Google Patents

Rare particle detection method and apparatus Download PDF

Info

Publication number
EP2990795B1
EP2990795B1 EP15188512.6A EP15188512A EP2990795B1 EP 2990795 B1 EP2990795 B1 EP 2990795B1 EP 15188512 A EP15188512 A EP 15188512A EP 2990795 B1 EP2990795 B1 EP 2990795B1
Authority
EP
European Patent Office
Prior art keywords
aliquot
rare
flow
fluid sample
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15188512.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2990795A1 (en
Inventor
Daniel T. Chiu
Peggy G. SCHIRO
Jason S. Kuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Priority to EP17187038.9A priority Critical patent/EP3299812B1/en
Publication of EP2990795A1 publication Critical patent/EP2990795A1/en
Application granted granted Critical
Publication of EP2990795B1 publication Critical patent/EP2990795B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N22/00—Investigating or analysing materials by the use of microwaves or radio waves, i.e. electromagnetic waves with a wavelength of one millimetre or more
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G01N33/5304—Reaction vessels, e.g. agglutination plates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Body fluids are complex suspensions of biological particles in liquid.
  • Blood for example, includes plasma and cells (red blood cells, white blood cells, platelets) and the cells occupy about 55% of blood.
  • Plasma is mostly water and it transfers proteins, ions, vitamins, enzymes, hormones, and other chemicals to cells in the body.
  • Red blood cells are about 6 to 8 ⁇ m in size and serve to provide oxygen to cells.
  • White blood cells are about 10 to 13 ⁇ m in diameter and they defend the body from disease as a part of an immune system by fighting against foreign viruses and bacteria. Platelets are the smallest cells, 1.5 to 3 ⁇ m, and they stop bleeding by forming blood clots.
  • Fluids in addition to blood such as saliva, tear, urine, cerebral spinal fluid as well as other body fluids in contact with various organs (e.g. lung) contain mixtures of cells and bioparticles.
  • the type and amount of cells and bioparticles that are present in a particular body fluid e.g. blood
  • a particular body fluid e.g. blood
  • Some cells or bioparticles are present in rare quantities compared to the nominal concentrations of blood cells. Despite their rare occurrence, these cells or bioparticles may be intricately tied to significant events that take place in the body that alter the health state of an individual. These cells are commonly referred to as "rare cells”.
  • CTC Circulating Tumor Cells
  • DTC Disseminated Tumor Cells
  • CCC Circulating Cancer Cells
  • CEC Circulating Epithelial Cells
  • Occult Tumor Cells or other similar permutations to indicate the mobile nature of these cells, in contrast to the specimens obtained by direct biopsy of solid tumors.
  • CTCs have been detected in the blood of patients suffering from all major cancers: prostate, ovarian, breast, gastric, colorectal, renal, lung, pancreatic, and others.
  • CTC test can also be used to monitor a patient's response to a particular treatment (e.g. radiation or chemotherapy) protocol. Based on the results of CTC test, a cancer patient may be able to avoid significant costs by minimizing additional unnecessary and expensive diagnostic tests and therapies, which are often times not covered by health insurance, for example Computed Tomography (CT) or Positron Emission Tomography (PET) scans, or shorten the drug treatments that are ineffective.
  • CT Computed Tomography
  • PET Positron Emission Tomography
  • CTCs are present in extremely low concentration in the peripheral blood, estimated to be on the order of one tumor cell per 10 6 to 10 7 mononuclear cells, which is equivalent to one tumor cell per 0.5 ml to 5 ml of peripheral blood.
  • a sample with estimated 100 million mononuclear cells must be screened in order to detect at least one CTC with 99.995% certainty.
  • ADM automatic digital microscopy
  • flow cytometry may be employed to determine the presence or quantity of CTCs in a blood sample.
  • flow cytometry requires that the cells are organized linearly in a row and detect each cell singularly because simultaneous detection of two cells cannot be interpreted correctly using existing technology.
  • laser beams are focused such that they only illuminate a single particle at any given time. For example, if one nonfluorescent cell traverses the detection volume simultaneously with a fluorescent cell configured to be detectable by the flow cytometer, the nonfluorescent cell, being invisible to the flow cytometer, would be directed in the same trajectory as the fluorescent cell.
  • flow cytometry is not suitable for detecting or recovering rare cells. Detecting cells one at a time (serially) and making a decision on the trajectory of every cell is too time-consuming when analyzing a large number of cells. For example, since ten milliliter of blood contains approximately ten billion cells, at 100,000 cells per second, which is the highest sorting speed of state-of-the-art flow cytometer, it would take 100,000 second or 28 hours to completely sort the content of 10 mL. For rare cell, often 7-15 mL of blood is required to collect a statistically significant number of rare cells; using a flow cytometer to recover rare cells is an impractical consumption of clinical resources and can translate to a very high testing cost.
  • the present invention satisfies these and other needs by providing methods and apparatuses for the detection of rare particles in fluid samples.
  • US 2002/081569 A1 discloses methods for purification and/or identification of particles in a liquid sample.
  • US 5602042 A discloses a method for collection and transfer of particles from a liquid suspension to a glass slide.
  • US 2009/014360 A1 discloses methods for focussing particles suspended within a moving fluid into one or more localized stream lines.
  • the present disclosure provides methods and apparatuses that rapidly scan a large volume of a fluid for the detection and or quantitation of desired bioparticles by ranking aliquots.
  • the concept employed termed Ensemble-Decision Aliquot Ranking ("eDAR"), is particularly useful for detecting rare cells in biofluids.
  • the present disclosure provides a method for detecting a rare particle in a fluid sample, the method comprising the steps of detecting the presence or absence of the rare particle in an aliquot of the fluid sample, assigning a value to the aliquot based on the presence or absence of the rare particle, and directing the flow or collection of the aliquot based on the assigned value.
  • the present disclosure provides a method for providing a subject a diagnosis or prognosis for a condition associated with the presence of a rare particle in a biological fluid, the method comprising the steps of detecting the presence or absence of the rare particle in an aliquot of the biological fluid, assigning a value to the aliquot based on the presence or absence of the rare particle, and providing a diagnosis or prognosis to the subject based on the assigned value.
  • the present disclosure provides a device for detecting a rare particle in a fluid sample, the device comprising at least a first input channel, at least two exit channels, at least one detector capable of detecting one or more rare particles in an aliquot of the fluid sample, a mechanism for directing the flow of the aliquot, and a computer capable of assigning a value to the aliquot based on the presence, absence, identity, composition, or quantity of the rare particles in the aliquot, wherein the computer is in communication with the detector and the mechanism for directing the flow of the aliquot.
  • the present disclosure provides methods and apparatuses for detecting and/or recovering rare particles in a fluid sample.
  • the concept embodied in this aspect is referred to herein as "Ensemble-Decision Aliquot Ranking" or "eDAR.”
  • the eDAR methodology can be characterized as (i) detecting the presence of absence of a rare particle in an aliquot of the fluid sample, (ii) ranking the aliquot according to the presence or absence of a rare particle, and (iii) directing the flow or collection of the entire aliquot based on the assigned ranking.
  • eDAR offers a tremendous advantage in speed. As an example of this, consider a 10-mL cell suspension containing 10 desired rare cells. In this case, about 99.9999% of the suspension volume does not contain a single desired rare cell.
  • Existing technologies such as flow cytometry, FACS, etc., invariably scan serially through every cell contained within the entire suspension volume, resulting in nearly all of time wasted scanning through the 99.9999% of the suspension volume that does not contain a desired cell.
  • eDAR allows a quick high-level screening of the entire suspension by aliquoting the suspension. If the cells are indeed rare, most aliquots will not contain any desired cells. In one aspect of the present disclosure, these aliquots are ranked as null and discarded through a first channel. In comparison, the few aliquots that do contain rare cells are ranked as nonzero and collected in a separate channel or chamber.
  • Flow cytometry operates by (1) flowing bioparticles in single file ( i.e., one by one in a row) through the use of a sheath flow to contain the particle-row, (2) detecting only one bioparticle at a time, and (3) determine the trajectory of the bioparticle detected. If the detected bioparticle is desired, for example, the bioparticle is directed, through a one of a variety of methods, to follow a certain trajectory to reach a collection container. If the detected bioparticle is undesirable, the bioparticle is directed in a different trajectory to reach a different collection container.
  • eDAR interrogates entire aliquots, i.e., three-dimensional subdivisions of a fluid, to make an ensemble decision for the entire aliquot.
  • aliquoting offers a much higher throughput.
  • Flow cytometry is incapable of analyzing an aliquot because the detectors are configured only collect signals from a single cell or a single plane of cells.
  • Bioparticles outside of the detection point or plane are entirely invisible to the detectors used in flow cytometers and consequently sheath flow, guiding buffers, or other hydrodynamic or geometric focusing mechanisms are necessary to prevent migration of bioparticles outside of the detection point or plane.
  • eDAR analyzes an entire aliquot which spans more than one plane or layer of bioparticles. In eDAR, signals emanating from an entire aliquot, as opposed to a single detection point or plane, are analyzed.
  • eDAR offers significantly increased sensitivity over existing methods to detect or isolate rare cells.
  • the detection components of eDAR can detect a single photon emanated within the entire aliquot and thus no bioparticle exhibiting detectable characteristic is missed.
  • the rate of false-negative is extremely low because aliquot ranking is configured to eliminate only aliquots that are ranked to be completely devoid of desired bioparticles.
  • Embodiments in accordance with the present invention may be used in a wide variety of applications in biology and diagnosis of disease, including capturing cancer cells or cancer stem cells from body fluids for cancer prognosis; parasites such as giardia or cryptosporidium for water quality monitoring; malaria-infected erythrocytes for malaria diagnosis; lymphocytes and leucocytes for HIV monitoring; fetal cells in maternal blood for disease screening; stem cells for therapy; prion-infected cells for prion-related (e.g. mad cow) disease screening.
  • parasites such as giardia or cryptosporidium for water quality monitoring
  • malaria-infected erythrocytes for malaria diagnosis
  • lymphocytes and leucocytes for HIV monitoring
  • fetal cells in maternal blood for disease screening stem cells for therapy
  • prion-infected cells for prion-related (e.g. mad cow) disease screening.
  • CD4+ T-lymphocytes CD4+ T-cells
  • HAV Human Immunodeficiency Virus
  • the absolute CD4+ T-lymphocyte count can serve as a criterion to initiate antiretroviral therapy and opportunistic infection prophylaxis in HIV-infected patients.
  • the reduction of CD4+ T-lymphocytes which is a subpopulation of leucocytes (white blood cells), strongly correlates to the decline of the immunological defense.
  • Monitoring of CD4+ T-lymphocytes (CD4+ T-cells) level every 3-6 months in all HIV-infected persons has been recommended by the CDC Public Health Service as a way to initiate appropriate treatment strategies and to evaluate treatment efficacy.
  • the absolute CD4+ T-cell number is established using the product of three laboratory techniques: the total white blood cell count, the percentage of white blood cells that are lymphocytes, and the percentage of lymphocytes that are CD4+ T-cells.
  • Single platform flow cytometers such as FACSCount (BD Biosciences) are commercially unavailable in developing countries or as a portable device.
  • Embodiments according to the present subject matter can be used to rapidly distinguish CD4+ T-lymphocytes from other leucocytes and RBCs.
  • Additional possible applications for separation, concentration, and/or isolation addressed by embodiments in accordance with the present invention include fetal cell monitoring in maternal blood for prenatal diagnostic of genetic disorders and prion detection.
  • a prion includes a small infectious proteinaceous particle which resists inactivation by procedures that modify nucleic acids.
  • embodiments according to the present subject matter can be used with fetal cells or other micro-biological particulates or nano-biological particulates.
  • a "fluid sample” refers to any liquid that may or may not contain a rare particle of interest.
  • the fluid sample may be a biological fluid sample, for example a blood sample, plasma sample, saliva sample, urine sample, lymph sample, spinal fluid sample, and the like.
  • the sample may be an environmental fluid sample, for example from a lake, river, ocean, pond, stream, spring, marsh, reservoir, or the like.
  • the sample may be a water sample, for example from a desalinization plant, water treatment plant, reservoir, spring, stream, glacial water flow, water tower, or other water source that may be contemplated as a source of potable water.
  • a "rare particle” refers to a cell or macromolecule present in a fluid sample at a low level.
  • a rare particle may be a cell, protein, protein complex, nucleic acid, nucleoprotein complex, carbohydrate, metabolite, catabolite, and the like.
  • a particle may be considered rare if it is present in a fluid sample at a concentration of less than about 10% of the total particle population in the fluid, or at less than about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, or less of the total particle population in the fluid.
  • the rare particle may be present in a fluid sample at less than about 1 part per 10 3 of the total particle population in the fluid, or at less than about 1 part per 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , or less of the total particle population in the fluid.
  • the rare particle is a rare cell.
  • Rare cells may be nucleated or non-nucleated.
  • Rare cells include, but are not limited to, cells expressing a malignant phenotype; fetal cells, such as fetal cells in maternal peripheral blood, tumor cells, such as tumor cells which have been shed from tumor into blood or other bodily fluids; cells infected with a virus, such as cells infected by HIV, cells transfected with a gene of interest; and aberrant subtypes of T-cells or B-cells present in the peripheral blood of subjects afflicted with autoreactive disorders.
  • an “ensemble-decision” refers to a decision made based on the detection of the presence or absence of a characteristic in an ensemble, or a group, of particles.
  • an ensemble-decision will be made based on the presence or absence of a single distinct particle in an aliquot of a fluid sample containing a plurality of particles.
  • ensemble-decisions made based on the presence or absence of a single particle will be applied to the entire aliquot ( i.e., to all of the particles present in the aliquot).
  • an "aliquot” refers to a portion of the total volume of a fluid sample to be analyzed.
  • An aliquot occupies a three-dimensional space and the particles within distribute randomly without organization.
  • An aliquot has a finite depth, and particles may distribute along the depth with no discernible layers.
  • an aliquot is analyzed in its entirety without sub-division. Sheet, ribbon, plane or similar terms suggesting two-dimensional spaces and used to describe current cell sorting methods (e.g., flow cytometry, FACS, etc. ) that typically employ hydrodynamic focusing are not considered an aliquot.
  • an aliquot may consist of a fraction of a larger fluid sample, for example, about 1/2 of a fluid sample, or about 1/3, 1/4, 1/5, 1/6, 1/7, 1/8, 1/9, 1/10, or less of a fluid sample.
  • an aliquot may consist of, for example, about 10% of a fluid sample, or about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, 0.001%, or less of a fluid sample.
  • a fluid that is to be examined or processed by an eDAR methodology provided herein may be divided, for example, into at least about 2 aliquots, or at least about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100,000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1 million, 2 million, 3 million, 4 million, 5
  • an aliquot may have a volume, for example, of between about 0.1 nL and about 10 mL, or between about 1 nL and about 1mL, or between about 1 nL and about 100 ⁇ L, or between about 1 nL and about 10 ⁇ L, or between about 1 nL and about 1 ⁇ L, or between about 1 nL and about 100 nL.
  • an aliquot refers to assessing a quantitative property, qualitative property, or importance of an aliquot by categorization.
  • an aliquot may be ranked as either null (for example, when a rare particle is not detected in the aliquot) or nonzero (for example, when at least one rare particle is detected in an aliquot).
  • the ranking may be binary.
  • an aliquot may be ranked according to additional categories, for example, which correlate with the concentration of the rare particle in the aliquot, the identity of the rare particle in the aliquot, the identities of a plurality of different rare particles in the aliquot, and the like.
  • any number of categories may be assigned based on ranges of concentration, for example, between about 1 and 10, between about 11 and 20, between about 1 and 50, between about 51 and 100, between about 1 and 100, between about 101 and 201, etc.
  • These rankings may be assigned an arbitrary number corresponding to one of a number of predetermined quantitative or qualitative categories ( e.g., 0, 1, 2, 3, 4, 5, etc.), or a number corresponding to an actual value for the number or approximate number or rare particles in the aliquot.
  • a "detectable characteristic” refers to a property associated with a rare particle, for example, a photoactive, electroactive, bioactive, or magnetic property that is intrinsic to the rare particle or which is associated with a detectable moiety bound to or conjugated to the rare particle.
  • photoactive properties include, for example, alterations in optical intensity (optical reflection, scattering, deflection, transmission, or absorbance) commonly induced by bioparticle morphology (particle size, granularity, internal subcellular structures), fluorescence, immunofluorescence, and the like.
  • electroactive properties include, for example, changes in the electrical charge, oxidation state, spin state, capacitance, conductance, dielectric properties, electrophoretic mobility, or polarizability.
  • bioactive properties include, for example, detectable interactions with enzymes such as alkaline phosphatase (AP), horseradish peroxidase (HRP), ⁇ -Galactosidase and their chemiluminescent, colometric, or chemifluorescent substrates, which include but are not limited to TMB (3,3',5,5'-Tetramethylbenzidine), OPD (o-phenylene Diamine, ABTS (2,2'-azinodiethylbenzthiazoline sulfonate), chlornaphthol, AEC (3-amino-9-ethylcarbazole), DAB (Diaminobenzidine), pNPP (p-Nitrophenyl Phosphate), BCIP/NBT (Bromochloroindolyl Phosphate-Nitro blue Tetrazolium, and the like.
  • enzymes such as alkaline phosphatase (AP), horseradish peroxidase (HRP),
  • moieties that can be used to detect a rare particle include, without limitation, nanoparticles, microbeads, antibodies and fragments thereof, fluorescent antibodies, magnetic nanoparticles, polymer molecules, dye molecules, DNA or RNA molecules ( e.g. aptamers), lipid molecules, protein molecules, and the like.
  • an "antibody” refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen.
  • the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes.
  • Light chains are classified as either kappa or lambda.
  • Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
  • Antibodies can be polyclonal or monoclonal, derived from serum, a hybridoma or recombinantly cloned, and can also be chimeric, primatized, or humanized.
  • An exemplary immunoglobulin (antibody) structural unit comprises a tetramer.
  • Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light” (about 25 kD) and one "heavy” chain (about 50-70 kD).
  • the N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
  • the terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.
  • Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases.
  • pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)' 2, a dimer of Fab which itself is a light chain joined to V H -C H 1 by a disulfide bond.
  • the F(ab)' 2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)' 2 dimer into an Fab' monomer.
  • the Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed.
  • antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology.
  • the term antibody also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature, 348:552-554 (1990 )).
  • the antibody is conjugated to a label or detectable moiety.
  • a "label” or a “detectable moiety” refers to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means.
  • useful labels include, without limitation radionuclides, fluorescent dyes (e.g., fluorescein, fluorescein isothiocyanate (FITC), Oregon Green TM , rhodamine, Texas red, tetrarhodimine isothiocynate (TRITC), Cy3, Cy5, etc.), fluorescent markers (e.g., green fluorescent protein (GFP), phycoerythrin, etc.), autoquenched fluorescent compounds that are activated by tumor-associated proteases, enzymes (e.g., luciferase, horseradish peroxidase, alkaline phosphatase, etc.), nanoparticles, biotin, digoxigenin, and the like.
  • fluorescent dyes e.g., fluorescein, fluorescein isothi
  • detection reagents may be perfused to selectively label or accentuate the isolated cells.
  • reagents include, without limitation, fluorescent, immunofluorescent, dye-conjugated molecules (such as antibodies, fab fragments, aptamers, polymers, ligands, agonists, antagonists, or combinations thereof) magnetic, electroactive, bioactive, or photoactive compounds.
  • fluorescent, immunofluorescent, dye-conjugated molecules such as antibodies, fab fragments, aptamers, polymers, ligands, agonists, antagonists, or combinations thereof
  • magnetic, electroactive, bioactive, or photoactive compounds such as antibodies, fab fragments, aptamers, polymers, ligands, agonists, antagonists, or combinations thereof
  • electroactive bioactive
  • bioactive or photoactive compounds.
  • An example is to use a stain that reacts with cytokeratins, which are integral components of the cytoskeleton in epithelial cancerous cells.
  • dye examples include fluorescein isothiocyanate (FITC)-conjugated mouse anti-human epithelial antibody (HEA) and phycoerythrin (PE)-conjugated anti-CD45.
  • Other examples of dye-conjugated antibodies include but are not limited to the pan-cytokeratin antibody A45B/B3, AE1/AE3, or CAM5.2 (pan-cytokeratin antibodies that recognize Cytokeratin 8 (CK8), Cytokeratin 18 (CK18), or Cytokeratin 19 (CK19) and ones against: breast cancer antigen NY-BR-1 (also known as B726P, ANKRD30A, Ankyrin repeat domain 30A); B305D isoform A or C (B305D-A ro B305D-C; also known as antigen B305D); Hermes antigen (also known as Antigen CD44, PGP1); E-cadherin (also known as Uvomorulin, Cadherin-1, CDH1); Carcino-embr
  • a rare particle for example a protein, nucleic acid, or cell
  • the specified antibodies bind to a particular rare particle at least two times the background and more typically more than 10 to 100 times background.
  • Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular particle.
  • polyclonal antibodies can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with the selected antigen and not with other proteins. This selection may be achieved by subtracting out antibodies that cross-react with other molecules.
  • the present invention provides a method for detecting one or more rare bioparticles in a sample fluid; said method comprising: a) interrogating one or more aliquots of said sample fluid; b) in a single measurement detecting presence or absence of said one or more rare bioparticles in each of said one or more aliquots wherein at least one of said one or more aliquots comprises multiple bioparticles; and c) ranking said aliquots based on the presence or absence of said one or more rare bioparticles.
  • the rare bioparticles are cells.
  • the rare bioparticles are fluorescent labeled cells.
  • multiple parameters are detected in a single measurement.
  • the multiple parameters are different fluorescent colors.
  • the sample fluid is stabilized by addition of anticoagulants, compounds that prevent agglomeration of cells in the sample including said bioparticles or their combinations.
  • the aliquot ranking is binary, for example an aliquot is assigned a value of "0" if the aliquot does not contain a rare article and a value of "1" if it does.
  • the ranking is non-binary, for example, the value is assigned based on the number or rare particles present in the aliquot or the identity of the rare particles in the sample.
  • the ranking is performed by a computer and a software representing a ranking algorithm.
  • the methods provided herein further comprise a step of channeling the aliquots based on their ranking. For example, the flow or collection of the aliquots is directed based on the value assigned to the aliquot. In certain embodiments, this is achieved by the use of external fields or by creating flow disturbances.
  • the method may comprise concentrating the rare bioparticles by collecting and/or pooling aliquots with similar said ranking.
  • the rare bioparticles are selected from the group consisting of cancer cells, cancer stem cells, giardia, cryptosporium, malaria infected erythrocytes, lymphocytes, leucocytes, fetal cells, stem cells and prion-infected cells.
  • the present invention provides a device for detecting one or more rare bioparticles in a sample fluid; said device comprising: a) one or more detectors for detecting presence or absence of one or more rare bioparticles in each of the one or more aliquots wherein at least one of said one or more aliquots comprises multiple bioparticles; and b) a computer with software for ranking said aliquots based on presence or absence of said one or more rare bioparticles.
  • the ranking is binary. In other embodiments, wherein the device is used to detect multiple types of bioparticles, the ranking is non-binary.
  • the device may further comprise channels for channeling said aliquots based on said ranking.
  • the channels are treated with anticoagulant compounds, compounds that preferentially bind to the rare bioparticles, compounds that prevent bioparticles agglomeration or their combinations.
  • the device may further comprise electrodes for tracking and manipulating the trajectory of said bioparticles.
  • the device may further comprise magnetic elements for the separation of bioparticles with attached magnetic particles.
  • the device may further comprise acoustical elements for tracking and manipulating the trajectory of said bioparticles.
  • the device comprises one or more detectors are selected from a camera, an electron multiplier, a charge-coupled device (CCD) image sensor, a photomultiplier tube (PMT), an avalanche photodiode (APD), a single-photon avalanche diode (SPAD), or a complementary metal oxide semiconductor (CMOS) image sensor.
  • a camera an electron multiplier, a charge-coupled device (CCD) image sensor, a photomultiplier tube (PMT), an avalanche photodiode (APD), a single-photon avalanche diode (SPAD), or a complementary metal oxide semiconductor (CMOS) image sensor.
  • CCD charge-coupled device
  • PMT photomultiplier tube
  • APD avalanche photodiode
  • SPAD single-photon avalanche diode
  • CMOS complementary metal oxide semiconductor
  • the device may further comprise one or more sources for interrogating one or more aliquots of said sample fluid.
  • a source of electromagnetic radiation for example, a source of electromagnetic radiation.
  • the one or more sources for interrogating are selected from, a laser (solid state, diode-pumped, ion, or dye), a light-emitting diode (LED), a lamp, an arc discharge, a magnetic pulse, or a natural light.
  • a source for interrogation of the aliquot is not required when the bioparticle exhibits light emission such as chemiluminescence or bio luminescence.
  • the present invention provides a method for detecting a rare particle in a fluid sample, the method comprising the steps of: (a) detecting the presence or absence of the rare particle in an aliquot of the fluid sample; (b) assigning a value to the aliquot based on the presence or absence of the rare particle; and (c) directing the flow or collection of the aliquot based on the assigned value.
  • the step of detecting the presence of the rare particle comprises the sub-steps of: (i) contacting the fluid sample with a detection reagent under conditions suitable to transform the detection reagent into a complex comprising said detection reagent and a rare particle; and (ii) detecting the presence or absence of a complex formed in step (i) in an aliquot of the fluid sample.
  • the detection reagent may comprise a labeled or unlabeled antibody, fab fragment, aptamer, polymer, nanoparticle, microbead, fluorescent antibody, magnetic nanoparticle, polymer molecule, dye molecule, aptamer, lipid molecule, protein molecule, and the like.
  • the step of detecting the presence of the rare particle comprises the sub-steps of: (i) interrogating the aliquot with an external source of electromagnetic radiation; and (ii) detecting fluorescence of the rare particle.
  • the rare particle may comprise a fluorescently labeled cell.
  • the fluorescently labeled cell may comprise a cell that expresses a fluorescent protein, or a cell that has been labeled with a fluorescent detection reagent.
  • a cell that transiently or stably expresses a red or green fluorescent protein may be used.
  • the step of detecting the presence of a rare particle comprises detecting bioluminescence or chemiluminescence of the rare particle.
  • the rare particle may be a cell, protein, protein complex, nucleic acid, nucleoprotein complex, carbohydrate, metabolite, catabolite, and the like.
  • the rare particle is a cell.
  • the cell may be a cancer cell, a circulating tumor cell (CTC), a cancer stem cell, a cancer cell displaying a cancer surface antigen, for example, one selected from the groups consisting of CD44, CD2, CD3, CD10, CD14, CD16, CD24. CD31, CD45, CD64, CD140b, or a combination thereof.
  • Cancer stem cells may be distinguished from ordinary cancer cells by perfusing other reagents that selectively bind to biomarkers, which may include but are not limited to CD44, CD2, CD3, CD10, CD14, CD16, CD24. CD31, CD45, CD64 or CD140b.
  • cells contained within the aliquots identified as having a rare cell may be further individually dissected.
  • these cells may be further partitioned or sorted via traditional flow cytometry or eDAR and desired cells may be dissected to understand the origin of malfunctioning cellular machinery.
  • the contents within each cell may be individually analyzed for DNA, RNA, DNA sequence, metabolite, lipid, carbohydrate, protein content, or the like.
  • the rare cell may be a parasitic cell or organism, for example, a species of Giardia or Cryptosporidium, a erythrocyte infected with a species of Plasmodium, a lymphocyte or leucocyte infected with HIV, a fetal cell in maternal blood, a stem cell, a prion-infected cell, a CD4+ T-cell, and the like.
  • a parasitic cell or organism for example, a species of Giardia or Cryptosporidium, a erythrocyte infected with a species of Plasmodium, a lymphocyte or leucocyte infected with HIV, a fetal cell in maternal blood, a stem cell, a prion-infected cell, a CD4+ T-cell, and the like.
  • the fluid sample may comprise more than one type of rare particle, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more types of rare particles. Accordingly, in certain embodiments, the fluid sample is simultaneously contacted with a plurality of differentiable detection reagents each having a different specificity under conditions sufficient to transform the plurality of detection reagents into a plurality of complexes comprising the detection reagents and a plurality of rare particles. In some embodiments, the plurality of complexes are detected simultaneously, for example, by using an eDAR apparatus that comprises more than one interrogation devices and/or more than one detection devices.
  • each rare particle may be contacted with a differentiable detection reagent, each of which may be detected by one of two detection devices.
  • the detection reagents comprise fluorescent moieties
  • two interrogation devices e.g., two lasers producing radiation at different wavelengths corresponding to excitation wavelengths of the different fluorescent moieties
  • the respective fluorescent radiation may be detected by two different detection devices.
  • the detection reagents are differentiable by fluorescence at different wavelengths.
  • the two or more rare particles may be detected in series.
  • the method may comprise detecting a first rare particle at a first location of an eDAR apparatus and detecting a second rare cell at a second location of an eDAR apparatus.
  • the aliquot in which the first and second particle reside may be channeled after the first detection step, after the second detection step, or after both detection steps.
  • detection of a characteristic from an ensemble of cells can be simultaneous or cumulative over time.
  • detection of a characteristic can emanate at once ("simultaneous") from a large aliquot containing an ensemble of bioparticles.
  • the bioparticles may be carried by a flow of variable velocity.
  • bioparticles may be carried by a steady flow as they traverse through the detection volume.
  • the flow may be stopped, decelerated, or accelerated as the cells traverse through the detection volume.
  • Flow may be regulated with one of the following either upstream or downstream of the detection volume: a valve, a bubble, an electric field, a magnetic field, an optical field, a pneumatic pressure source, a solid particle, a membrane, an immiscible droplet, a gravitational differential, or a coating to alter surface tension of the channel.
  • the detection step is performed during continuous flow of the fluid sample through a flow channel.
  • the individual aliquots are not physically separated, but rather are defined by the optical detection step, i.e., an aliquot may be defined as the ensemble of particles present in the detection volume at the instant the detection occurs.
  • the detection event will occur with a regular frequency, which is dependent upon both the size of the detection volume and the flow rate of the fluid sample. For example, if the detection volume of a particular apparatus is 10 ⁇ L and the fluid sample is flowed through the apparatus at a rate of 100 ⁇ L / second, a different aliquot will be detected every 0.1 seconds, or at a rate of 10 Hz.
  • discrete aliquots traverse through the detection volume at a rate between 0.1 kHz and 100 MHz. In another embodiment, the discrete aliquots traverse through the detection volume at a rate between about 10 Hz and about 10MHz. In other embodiments, the discrete aliquots may traverse through the detection volume at a frequency of between about 0.1 kHz and about 100 MHZ, or between about 1 kHz and about 10 MHz, or between about 1kHz and about 5MHz, or between about 1 kHz and about 1 MHz.
  • the frequency by which the aliquots traverse through the detection volume may be at least about 0.1 kHz, or at least about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 125, 150, 200, 250, 300, 400, 500, 600, 700, 800, or 900 kHz, or at least about 1 MHz, or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 MHz.
  • detection of a characteristic from an ensemble of cells can emanate over time (“cumulative") from a small detection volume which is on the order of a single cell, but with multiple cells traversing through the detection volume with the aid of flow.
  • Cumulative mode of eDAR is distinct from time-lapse overlay of consecutive signals or frames emanating from a single bioparticle; timelapse overlay of a single bioparticle does not constitute an ensemble of bioparticles.
  • a decision is rendered only after a characteristic from an ensemble of cells has been detected.
  • the aliquots may be physically separated prior to detection. This may be accomplished, for example, by partitioning the sample fluid into discrete aqueous aliquots separated by air or a continuous oil-immiscible fluid phase, for example, into a droplet.
  • the immiscible phase used to separate aqueous aliquots may include an organic phase, an oil, natural oils such as mineral oil and soybean oil, silicone oils such as AR-20, AS-4, PDMS oil, fluorinated oils such as Fluorinert and perfluorordecalin, organic solvents such as hexadecane and acetophenone, a wax, air, or gas.
  • natural oils such as mineral oil and soybean oil
  • silicone oils such as AR-20, AS-4, PDMS oil
  • fluorinated oils such as Fluorinert and perfluorordecalin
  • organic solvents such as hexadecane and acetophenone, a wax, air, or gas.
  • an immiscible phase may be continuous ( i.e. surrounds the discrete aliquots entirely) or segmented ( i.e. occupies only the spacing between discrete aliquots but does not completely surround the aliquots).
  • Figure 16 illustrates a an immiscible phase (1642) that surrounds the discrete aliquots entirely.
  • the discrete aliquots are droplets. In another embodiment, the discrete aliquots are plugs.
  • the discrete aliquots may be formed sequentially on an eDAR apparatus in a flow channel in fluidic communication with the flow channel.
  • the discrete aliquots may be formed externally of the eDAR apparatus but flowed into a flow channel of the apparatus via a tubing, a port, or an interconnect in fluidic communication with the flow channel.
  • surfactants may be added to the cell suspension or the immiscible phase to stabilize the discrete aliquots.
  • Surfactants may include albumin (bovine or human serum albumin), Span 80, Pluronic, octaethylene glycol monodecyl ether, tetraethylene glycol monodecyl ether, zwitterionic surfactants such as N-dodecyl-N, N-dimethyl-3-ammonio-1-propanesulfonate (DDAPS), anionic surfactants such as sodium dioctyl sulfosuccinate (AOT), cationic surfactants such as cetyl trimethyl ammonium bromide (CTAB), and silicone-based, PEGylated and fluorinated surfactants.
  • albumin bovine or human serum albumin
  • Span 80 Pluronic
  • octaethylene glycol monodecyl ether tetraethylene glycol monodecyl ether
  • the fluid sample may be partitioned into aliquots and physically separated into separate flow channels or chambers of an eDAR apparatus prior to the detection step.
  • the subsequent detection step may then be performed either in parallel ( i.e., at the same time using multiple detection devices or a single detection device), or sequentially, for example by directing the individual aliquots sequentially through one or more detection volumes.
  • the fluid sample for example a biological fluid sample, may be stabilized prior to detection of a rare particle.
  • the fluids may be stabilized with a reagents, including but not limited to, an anticoagulant such as citrate, heparin, ethylenediamine tetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA), 1,2-diaminocyclohexane tetraacetic acid (DCTA), or ethylene bis(oxyethylenenitrilo) tetraacetic acid (EGTA); an aldehyde such as methylol, hydroxymethyl derivatives of amines or amides of formaldehyde, diazolinidinyl urea, imidazolidinyl urea, methenamine, paraformaldehyde, glutaraldehyde, or glyoxal, and the like.
  • an anticoagulant such as citrate, heparin, ethylenediamine tetraacetic acid (
  • the methods provided herein may be further coupled to a secondary process occurring after channeling of the desired aliquots.
  • Example of processes and/or functions that may be coupled to a method provided herein include, for example, selective reactions to identify cellular contents (e.g. DNA, RNA, microRNA, lipids, metabolites, carbohydrates, or proteins encapsulated within cells). These reactions include Polymerase Chain Reaction (PCR), Real-Time Polymerase Chain Reaction (RT-PCR), isothermal PCR, reactions to determine the epigenetic states of DNA, single-molecule hybridization reactions to determine the microRNA and siRNA contents, or aptamer (short strands of DNA)-selective reactions.
  • PCR Polymerase Chain Reaction
  • RT-PCR Real-Time Polymerase Chain Reaction
  • aptamer short strands of DNA
  • the methods provided herein may further be coupled to an assay protocol following aliquot or cell isolation.
  • assays include nucleic-acid based methods such as RNA extraction (with or without amplification), cDNA synthesis (reverse transcription), gene microarrays, DNA extraction, Polymerase Chain Reactions (PCR) (single, nested, quantitative real-time, or linker-adapter), or DNA-methylation analysis; cytometric methods such as fluorescence in situ hybridization (FISH), laser capture microdissection, flow cytometry, fluorescence activated cell sorting (FACS), cell culturing, or comparative genomic hybridization (CGH) studies; chemical assay methods such as electrophoresis, Southern blot analysis or enzyme-linked immunosorbent assay (ELISA); assays to determine the microRNA and siRNA contents; assays to determine the DNA/RNA content; assays to determine lipid contents; assays to determine carbohydrate
  • the methods provided herein may further be coupled to flow cytometry, for example, to further partition or isolate rare particles present in a selected aliquot.
  • a channel of the eDAR device used for the methods provided herein may be in fluidic communication with a flow cytometer.
  • the coupling of eDAR and flow cytometry allows for selected aliquots to be further examined or serially sorted to further enrich a population of rare particles or cells.
  • this configuration allows for upstream gross-sorting of rare particles or cells and only directs aliquots containing rare particles or cells into downstream processes, such as flow cytometry, that are time, cost, and/or labor intense.
  • the methods provided herein may be performed using an eDAR apparatus provided herein.
  • an aliquot comprises more than a single particle, cell, or fluorescent entity.
  • discreet volumes containing a plurality of cells or particles, rather than single cells or particles, or 1 dimensional sheets of cells or particles, can be interrogated simultaneously.
  • the particles or cells of a fluid do not need to enter the detection spot or volume serially ( i.e., one after another without overlapping presence). In a related embodiment, the particles do not need to enter the detection spot or volume in a single row or sheet. Accordingly, in one embodiment of the methods provided herein, multiple bioparticles, within a single aliquot, may pass through a cross-section or cross-sectional volume of a flow channel, for example an interrogation and/or detection volume, at a time.
  • a sheath flow, guiding buffer, or other hydrodynamic or geometric focusing mechanisms is not needed to focus the bioparticles into a single row for interrogation and/or detection.
  • a ranking scheme or value assignment scheme of complete aliquots is employed, instead of sorting individual bioparticles.
  • an ensemble of particles or cells is detected simultaneously, for example as a single aliquot of a larger fluid sample.
  • a decision made for an aliquot affects the entire ensemble of particles or cells contained within the aliquot.
  • an ensemble of particles or cells detected simultaneously within an aliquot will remain as an ensemble of particles or cells.
  • the aliquot is assigned either a first value is the aliquot contains a rare particle or a second value if the aliquot does not contain a rare particle.
  • the ranking i.e., assignment of a value
  • each aliquot containing at least one rare particle is assigned a value of 1, while each aliquot not containing a rare particle is assigned a value of 0.
  • the aliquot is assigned a value according to the quantity of rare particles present in the aliquot.
  • an aliquot containing 4 rare particles may be assigned a value of 4.
  • an aliquot containing 4 particles may be assigned a value that corresponds to a particular range of rare particle quantities, for example 0 to 5 particles, 1 to 10 particles 4 to 6 particles, etc.
  • an aliquot is assigned a value according to the identities of any rare particles in the aliquot. For example, wherein a fluid sample contains two rare particles, A and B, an aliquot containing neither A nor B may be assigned a value of 0, an aliquot containing only A may be assigned a value of 1, an aliquot containing only B may be assigned a value of 2, and an aliquot containing both A and B may be assigned a value of 3. Accordingly, in one embodiment of the methods provided herein, wherein more than one type of rare particles are present in a single fluid sample, the ranking ( i.e., assignment of a value) is not binary.
  • a non-null assigned value may depends on either the identity of the rare particle or the concentration of the rare particle.
  • multiple aliquots having the same assigned value are pooled or channeled together.
  • an active decision is required to rank or assign a value to an aliquot.
  • a computer, controller, chip with integrated circuits, circuit board, electronic element, software, and/or algorithm is used to rank or assign a value to an aliquot.
  • directing the flow or collection of an aliquot is based on the value assigned to the aliquot. For example, in an embodiment wherein a single type of rare particle is present in a fluid sample, an aliquot assigned a null or "0" value may be directed into a first channel (channeled) or waste outlet and an aliquot assigned a positive or "1" value may be directed into a second channel or collection chamber.
  • an aliquot may be channeled based on the particular composition of rare particles present in the aliquot.
  • an aliquot containing no rare particles may be directed into a first channel or waste outlet
  • an aliquot containing a first type of rare particle may be directed into a second channel or a first collection chamber
  • an aliquot containing a second type or rare particle may be directed into a third channel or second collection chamber.
  • an aliquot containing more than one type of rare particle may be directed into a particular flow channel or collection chamber.
  • the aliquot may be directed into a mixing or dilution chamber and subsequently the mixed or diluted aliquot may be further partitioned into sub-aliquots such that the rare cells are partitioned into different sub-aliquots. The rare cells in the sub-aliquots may then be detected again such that the rare cells can be separated from each other.
  • the step of channeling i.e., directing the flow or collection of the aliquots may be performed by the use of external fields or by creating flow disturbances.
  • external fields may be used to alter the aliquot direction.
  • the fields may include electric field, magnetic field, electrokinetic, electrophoretic, dielectrophoretic, hydrodynamic, gravitational, pneumatic or optical forces.
  • external flow disturbances may be induced with an introduction of materials immiscible with cell suspension, such as air, immiscible organic liquid, or microbeads.
  • the flow can be delivered by, for example, methods and devices that induce hydrodynamic fluidic pressure, which includes but is not limited to those that operate on the basis of mechanical principles (e.g. external syringe pumps, pneumatic membrane pumps, vibrating membrane pumps, vacuum devices, centrifugal forces, and capillary action); electrical or magnetic principles (e.g. electroosmotic flow, electrokinetic pumps piezoelectric/ultrasonic pumps, ferrofluidic plugs, electrohydrodynamic pumps, and magnetohydrodynamic pumps); thermodynamic principles (e.g. gas bubble generation/phase-change-induced volume expansion); surface-wetting principles (e.g. electrowetting, chemically, thermally, and radioactively induced surface-tension gradient); and the like.
  • mechanical principles e.g. external syringe pumps, pneumatic membrane pumps, vibrating membrane pumps, vacuum devices, centrifugal forces, and capillary action
  • electrical or magnetic principles e.g. electroosmotic flow, electrokinetic pumps piezoelectric/ultrasonic pumps,
  • the fluid can be delivered or channeled by a fluid drive force provided by gravity feed, surface tension (like capillary action), electrostatic forces (electrokinetic flow), centrifugal flow (substrate disposed on a compact disc and rotated), magnetic forces (oscillating ions causes flow), magnetohydrodynamic forces and a vacuum or pressure differential.
  • a fluid drive force provided by gravity feed, surface tension (like capillary action), electrostatic forces (electrokinetic flow), centrifugal flow (substrate disposed on a compact disc and rotated), magnetic forces (oscillating ions causes flow), magnetohydrodynamic forces and a vacuum or pressure differential.
  • Fluid flow control devices such as those enumerated with regard to methods and devices for inducing hydrodynamic fluid pressure or fluid drive force, can be coupled to an input port or an output port of the present subject matter.
  • multiple ports are provided at either or both of the inlet and outlet and one or more ports are coupled to a fluid flow control device.
  • the present invention provides a method for providing a subject a diagnosis or prognosis for a condition associated with the presence of a rare particle in a fluid sample, for example a biological fluid such as a blood sample.
  • a fluid sample for example a biological fluid such as a blood sample.
  • the method comprises the steps of: (a) detecting the presence or absence of the rare particle in an aliquot of the biological fluid; (b) assigning a value to the aliquot based on the presence or absence of the rare particle; and (c) directing the flow or collection of the aliquot based on the assigned value.
  • the method comprises the steps of: (a) contacting a biological fluid from the subject with a detection reagent under conditions suitable to transform the detection reagent into a complex comprising said detection reagent and a rare particle; (b) detecting the presence or absence of a complex formed in step (a) in an aliquot of the biological fluid; (c) assigning a value to the aliquot based on the presence or absence of a complex formed in step (a); and (d) providing a diagnosis or prognosis to the subject based on the assigned value.
  • the step of detecting the presence of the rare particle comprises the sub-steps of: (i) interrogating the aliquot with an external source of electromagnetic radiation; and (ii) detecting fluorescence of the rare particle.
  • CTC Circulating Tumor Cells
  • the present invention offers a real-time snapshot of the cancer spreading process.
  • the most remarkable differentiation of a CTC blood test from the traditional prognostic tools e.g., status of lymph nodes, tumor size, and morphologic features
  • the CTC blood test can be used to provide early feedback on whether a cancer treatment is effective.
  • Patients undergoing the 6-month chemotherapy may have their CTC counts measured every 3-4 weeks; if the count remains high, the oncologist may deem the current treatment ineffective and prescribe new drugs. From the patients' perspective, having a CTC test can (1) provide a substantial savings by eliminating ineffective chemotherapy, which can cost between about $3,000-$10,000/month per drug, (2) grant them precious opportunities to find an effective treatment before it is too late.
  • the present invention provides a rapid, inexpensive CTC test that is cheaper, safer, more reproducible, and provides the same, if not more accurate, prognostic information six weeks earlier than a radiological imaging scan.
  • biomarker test available that offers similar advantages.
  • the methods described herein provide the potential of detecting cancer cells before their concentration reach the lower detection limit of competing technologies. This means that the methods provided herein are able to yield meaningful results earlier than competing technologies. Consequently, instead of limiting the use of the present technology to Stage IV metastatic cancer, oncologists may expand its use toward early diagnostic (i.e., Stage III, Stage II, Stage I, or metastatic, or pre-cancerous), for example by periodically prescribing the use of the methods provided herein to the general public not yet exhibiting symptoms of cancer. Generally healthy people do not have any CTCs in blood; if any CTC is detected in the unsuspecting patients using the present invention, then further tests, (e.g., CT, MRI,) can be prescribed to locate the tumors and confirm the status.
  • tumor cells isolated using the present invention may be further subjected to subpopulation analysis (e.g., according to genotype or phenotype) to develop a targeted treatment.
  • the isolated tumor cells can be incubated with fluorescent antibodies binding to specific drug targets to determine the presence or degree of expression of a drug target. Once the expression of the drug target is confirmed, an oncologist can be assured to choose from drugs specifically developed to target the expression.
  • the isolated tumor cells may be incubated with fluorescent antibodies binding specifically to Her2 receptor to determine whether the breast tumor shedding CTCs is Her2-positive.
  • Herceptin trimuzumab
  • BCR-ABL or PDGFR targeted by drug Gleevec
  • ERBB2 targeted by Herceptin
  • EFGR targeted by Iressa, Tarceva
  • RAR-alpha targeted by ATRA
  • Oestrogen receptor targeted by Tamoxifen
  • aromatase targeted by Letrazole
  • androgen receptor targeted by Flutamide, Biclutamide
  • CD20 targeted by Rituximab
  • VEGF-receptor targeted by Avastin
  • the rare particle is a cancer cell or circulating tumor cell (CTC).
  • the rare cell may be a parasitic cell or organism, for example, a species of Giardia or Cryptosporidium, a erythrocyte infected with a species of Plasmodium, a lymphocyte or leucocyte infected with HIV, a fetal cell in maternal blood, a stem cell, a prion-infected cell, a CD4+ T-cell, and the like.
  • a method for diagnosing malaria comprising detecting an erythrocyte infected with Plasmodium using an eDAR method and/or apparatus provided herein.
  • a method for diagnosing an HIV infection comprising detecting a lymphocyte or leucocyte infected with the HIV virus using an eDAR method and/or apparatus provided herein.
  • a method for diagnosing a disease associated with a prion comprising detecting a prior in a biological fluid from a human or other animal (e.g., a cow) using an eDAR method and/or apparatus provided herein.
  • the disease associated with a prion is mad cow disease.
  • the method comprises detecting a circulating tumor cell in a blood sample from a subject using an eDAR method and/or apparatus provided herein.
  • the subject may be a patient who has previously been diagnosed with Stage I, Stage II, Stage III, or Stage IV cancer.
  • the patient may be further diagnosed with metastatic cancer.
  • a method for diagnosing metastatic cancer in a subject that has previously been diagnosed with a solid tumor comprising the steps of: (a) detecting the presence or absence of a CTC in an aliquot of a blood sample from the subject; (b) assigning a value to the aliquot based on the presence or absence of the CTC; and (c) directing the flow or collection of the aliquot based on the assigned value.
  • the absence of CTCs in the blood sample is correlated with the subject not having metastatic cancer.
  • the presence of at least one CTC in the blood sample is correlated with the subject having metastatic cancer.
  • the presence of at least a reference number of CTCs in the blood is correlated with the subject having metastatic cancer.
  • the method may further comprise a step of (d) diagnosing the subject as not having metastatic cancer if no CTCs are detected in the blood sample or diagnosing the subject as having metastatic cancer if at least one CTC is detected in the blood sample.
  • a method for monitoring a subject diagnosed with cancer comprising detecting the presence or absence of a CTC in an aliquot of a blood sample from the subject using an eDAR method provided herein.
  • the patient may be monitored for the progression of cancer to metastatic cancer at regular intervals, for example, at least once a year, at least twice a year, or at least about 3, 4, 5, 6, 7, 8, 9, 10, or more times a year.
  • the subject may be monitored about once a month, or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times a month.
  • the absence of CTCs in the blood sample is correlated with the subject not having metastatic cancer.
  • the presence of at least one CTC in the blood sample is correlated with the subject having metastatic cancer.
  • the presence of at least a reference number of CTCs in the blood is correlated with the subject having metastatic cancer.
  • the method may further comprise a step of (d) diagnosing the subject as not having metastatic cancer if no CTCs are detected in the blood sample or diagnosing the subject as having metastatic cancer if at least one CTC is detected in the blood sample.
  • the method may further comprise a step of subjecting one or more aliquots identified as containing a CTC to further analysis to identify one or more characteristics of the CTC cell or cells.
  • a CTC is detected in a blood sample
  • the method may further comprise a step of subjecting one or more aliquots identified as containing a CTC to further analysis to identify one or more characteristics of the CTC cell or cells.
  • an aliquot or pool of aliquots containing a CTC may be contacted with one or more detection reagents specific for one or more cancer-specific surface antigens.
  • detection reagents specific for one or more cancer-specific surface antigens.
  • Non-limiting examples of cancer-specific surface antigens that can be assayed for include, without limitation, BCR-ABL or PDGFR (targeted by drug Gleevec), ERBB2 (targeted by Herceptin), EFGR (targeted by Iressa, Tarceva), RAR-alpha (targeted by ATRA), Oestrogen receptor (targeted by Tamoxifen), aromatase (targeted by Letrazole), androgen receptor (targeted by Flutamide, Biclutamide), CD20 (targeted by Rituximab), VEGF-receptor (targeted by Avastin), and the like. Accordingly, in certain embodiments, the method may further comprise a step of assigning a targeted therapy to the subject based on the detection of a specific surface antigen present on the CTC.
  • the further analysis can be performed using an eDAR method provided herein, for example by contacting the pooled aliquots with a plurality of differentially labeled detection reagents under conditions suitable to transform the detection reagents into complexes with the cancer-specific antigens present on the surface of the CTCs and detecting the complexes using a plurality of detection devices.
  • an eDAR method provided herein, for example by contacting the pooled aliquots with a plurality of differentially labeled detection reagents under conditions suitable to transform the detection reagents into complexes with the cancer-specific antigens present on the surface of the CTCs and detecting the complexes using a plurality of detection devices.
  • the further analysis can be performed by coupling the initial eDAR method with a traditional flow cytometry or immunochemical method (e.g., immunoblot, ELISA, xMAP multiplex assay, etc. ).
  • a traditional flow cytometry or immunochemical method e.g., immunoblot, ELISA, xMAP multiplex assay, etc.
  • the eDAR device used to detect the CTC may be in fluid communication with a second device or means for performing the further analysis.
  • the method may further comprise a step of assigning therapy for metastatic cancer to the subject.
  • a method for diagnosing a subject with cancer comprising detecting a CTC in a blood sample taken from the subject. For example, detecting a CTC in a blood sample from a subject that has not been previously diagnosed with cancer.
  • the subject may have an increased risk of having or developing cancer, for example, the subject may have a family history of cancer, be a smoker, or otherwise been exposed to a carcinogenic substance (i.e., asbestos, benzene, cadmium, radon, radioactivity, and the like).
  • a method for monitoring a subject that has not been previously diagnosed with cancer comprising the steps of: (a) detecting the presence or absence of a CTC in an aliquot of a blood sample from the subject; (b) assigning a value to the aliquot based on the presence or absence of the CTC; and (c) directing the flow or collection of the aliquot based on the assigned value.
  • the absence of CTCs in the blood sample is correlated with the subject not having metastatic cancer.
  • the presence of at least one CTC in the blood sample is correlated with the subject having cancer.
  • the presence of at least a reference number of CTCs in the blood is correlated with the subject having cancer or metastatic cancer.
  • the method may further comprise a step of (d) diagnosing the subject as not having cancer if no CTCs are detected in the blood sample or diagnosing the subject as having cancer if at least one CTC is detected in the blood sample.
  • the step of detecting the presence or absence of the CTC can be performed as described above, for example, by (i) contacting a biological fluid from the subject with a detection reagent under conditions suitable to transform the detection reagent into a complex comprising said detection reagent and a rare particle; and (ii) detecting the presence or absence of a complex formed in step (i) in an aliquot of the biological fluid, or by (i) interrogating the aliquot with an external source of electromagnetic radiation; and (ii) detecting fluorescence of the rare particle.
  • the present invention provides methods for providing a prognosis for a disease or condition associated with the presence of a rare particle in a biological fluid.
  • the method comprises the steps of: (a) detecting the presence or absence of the rare particle in an aliquot of a biological sample from a subject; (b) assigning a value to the aliquot based on the presence or absence of the rare particle; (c) directing the flow or collection of the aliquot based on the assigned value; and (d) providing either a good prognosis if no rare particles are detected in the sample or a poor prognosis if a rare particle is detected in the sample.
  • the aliquot is assigned a value based on the quantity or the identity of the rare particle in the aliquot.
  • a good or poor prognosis is provided based on the quantity of the rare particles in the sample. For example, in one embodiment, a good prognosis is provided if the quantity of the rare particles in the sample is less than a predetermined reference value and a poor prognosis is provided if the quantity of the rare particles in the sample is equal to or greater than the reference value.
  • a predetermined reference value may be associated with a likelihood of responding to a particular therapy or a likelihood of overall or disease free survival for a period of time, for example at least 6 month, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more years.
  • the step of detecting the presence or absence of the rare particle can be performed as described above, for example, by (i) contacting a biological fluid from the subject with a detection reagent under conditions suitable to transform the detection reagent into a complex comprising said detection reagent and a rare particle; and (ii) detecting the presence or absence of a complex formed in step (i) in an aliquot of the biological fluid, or by (i) interrogating the aliquot with an external source of electromagnetic radiation; and (ii) detecting fluorescence of the rare particle.
  • a method provided herein may be used to provide a prognosis for any disease associated with a rare particle.
  • a method for providing a prognosis for malaria comprising determining the number of erythrocytes infected with Plasmodium in a blood sample from an individual using an eDAR method and/or apparatus provided herein and providing either a good prognosis if the total number of infected erythrocytes detected in the blood sample is less than a predetermined reference value or a poor prognosis if the total number of infected erythrocytes detected in the sample is equal to or greater than the reference value.
  • a method for providing a prognosis for an HIV infection comprising determining the number of lymphocytes or leucocytes infected with an HIV virus in a blood sample from an individual using an eDAR method and/or apparatus provided herein and providing either a good prognosis if the total number of infected cells detected in the blood sample is less than a predetermined reference value or a poor prognosis if the total number of infected cells detected in the sample is equal to or greater than the reference value.
  • a method for providing a prognosis for a disease associated with a prion comprising determining the number of prions in a biological fluid sample from a subject using an eDAR method and/or apparatus provided herein and providing either a good prognosis if the total number of prions detected in the sample is less than a predetermined reference value or a poor prognosis if the total number of prions detected in the sample is equal to or greater than the reference value.
  • a predetermined reference value may be associated with a likelihood of responding to a particular therapy or a likelihood of overall or disease free survival for a period of time, for example at least 6 month, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more years.
  • the present invention provides a method for providing a prognosis for a subject diagnosed with a solid tumor.
  • the method comprises the steps of (a) detecting the presence or absence of a CTC in an aliquot of a blood sample from the subject; (b) assigning a value to the aliquot based on the presence or absence of the CTC; (c) directing the flow or collection of the aliquot based on the assigned value; and (d) providing either a good prognosis if no CTCs are detected or a poor prognosis if a CTC is detected.
  • a method for providing a prognosis for a subject diagnosed with metastatic cancer comprising the steps of (a) detecting the presence or absence of a CTC in an aliquot of a blood sample from the subject; (b) assigning a value to the aliquot based on the number CTCs detected in the aliquot; (c) directing the flow or collection of the aliquot based on the assigned value; and (d) providing either a good prognosis if the total number of CTCs detected in the blood sample is less than a predetermined reference value or a poor prognosis if the total number of CTCs detected in the sample is equal to or greater than the reference value.
  • a predetermined reference value may be associated with a likelihood of responding to a particular therapy or a likelihood of overall or disease free survival for a period of time, for example at least 6 month, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more years.
  • the present invention provides methods for monitoring the progression of a disease or the response to a therapy, the method comprising detecting a rare particle in a fluid sample using an eDAR method and/or apparatus provided herein.
  • the method comprises the steps of: (a) detecting the presence or absence of the rare particle in a plurality of aliquots of a first biological sample taken from a subject at a first time; (b) assigning a value to the aliquots based on the presence, absence, quantity, or identity of the rare particle; (c) determining the total value of all the aliquots from the first sample; (d) detecting the presence or absence of the rare particle in a plurality of aliquots of a second biological sample taken from the subject at a second time; (e) assigning a value to the aliquots based on the presence, absence, quantity, or identity of the rare particle; (f) determining the total value of all the aliquots from the second sample; and (g) comparing the total value assigned to the first sample to the total value assigned to the second sample, wherein an increased value assigned to the second sample as compared to the first sample is correlated with a progression of the disease and/or a poor response to the therapy and/
  • the aliquots may further be directed into a particular channel or chamber (channeled) based on the value assigned for collection, further enrichment, or further analysis.
  • methods of monitoring disease progression or response to therapy may be employed on a regular basis after diagnosis of the disease or initiation of the treatment regime. For example, samples may be collected from a subject at least once a year, at least twice a year, or at least about 3, 4, 5, 6, 7, 8, 9, 10, or more times a year. In some embodiments, the subject may be monitored about once a month, or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times a month.
  • the method may further comprise a step of assigning a therapy, increasing a dosage regime, changing a therapeutic regime, and the like.
  • the disease or condition associated with a rare particle may be cancer, malaria, HIV/Aids, a prion-related disease, or the like.
  • the present invention provides a method for monitoring water quality by detecting one or more rare particle contaminant in a sample of water using an eDAR method or apparatus provided herein.
  • the method comprises the steps of (a) detecting the presence or absence of a water contaminant in an aliquot of a sample taken from a water source; (b) assigning a value to the aliquot based on the presence, absence, quantity, or identity of the water contaminant in the aliquot; and (c) directing the flow or collection of the aliquot based on the assigned value, whereby the quality of the water source is determined based on the total value assigned to all of the aliquots detected in the method.
  • the water source may be a lake, pool, river, stream, or other natural body of water.
  • the water may be tested to determine or predict the impact a man made object or activity has or will have on the body of water or to assess the feasibility or safety of using the body of water to supply drinking water to a population.
  • the water source may be a pool or pond at a water treatment plant, a reservoir, a water tower, or other body of water collected for the purpose of supplying drinking water to a population.
  • the water may be tested to assess the feasibility or safety of using the body of water to supply drinking water to a population.
  • a method provided herein may be used to regularly monitor the quality of a water source used to supply drinking water to a population, for example at a water treatment plant or in a water tower or reservoir.
  • the water source may be monitored at least once a year, at least twice a year, or at least about 3, 4, 5, 6, 7, 8, 9, 10, or more times a year.
  • the subject may be monitored about once a month, or at least about 2, 3, 4, 5, or more times a month.
  • the water may be tested at least once a week, or at least 2, 3, 4, 5, 6, or more times a week, or at least daily or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times a day.
  • a method provided herein may be used to determine the feasibility or safety of using a body of water to supply drinking water to a population after a natural disaster (e.g., after a hurricane, tsunami, or earthquake), accident, or act of terrorism.
  • a natural disaster e.g., after a hurricane, tsunami, or earthquake
  • Methods of testing or monitoring water safety or quality may comprise the detection of a rare particle that is a water contaminant, for example a parasite such as a species of Giardia, Cryptosporidium, or other organic or inorganic water contaminant that when present at low quantities poses a public health risk.
  • a rare particle that is a water contaminant for example a parasite such as a species of Giardia, Cryptosporidium, or other organic or inorganic water contaminant that when present at low quantities poses a public health risk.
  • the present invention provides a device for detecting a rare particle in a biological fluid.
  • the device comprises: (a) at least a first input channel; (b) at least two exit channels; (c) at least one detector capable of detecting one or more rare particles in an aliquot of the biological fluid; (d) a mechanism for directing the flow of the aliquot; and (e) a ranking device capable of assigning a value to the aliquot based on the presence, absence, identity, composition, or quantity of the rare particles in the aliquot, wherein the computer is in communication with the detector and the mechanism for directing the flow of the aliquot.
  • the apparatus further comprises a source for interrogating the aliquot.
  • the apparatus may not require a source for interrogating the aliquot.
  • the apparatus provided herein may comprise a flow channel enclosed by walls and/or microfabricated on a substrate, with design features to minimize inadvertent damage to rare cells. Reducing inadvertent damage of rare cells reduces the rate of false-negative which could lead to erroneous patient diagnosis or prognosis.
  • the flow channel may further comprise channels with hydrodynamically designed apertures to exclude biological cells with minimal stress or damage as described in US Patent Application Nos. 2007/0037172 and 2008/0248499 .
  • Such channels referred to in the aforementioned patent applications as channels with one-dimensional ("1-D") apertures, reduce the hydrodynamic pressure experienced by the cells during the cell exclusion process and therefore reduce the likelihood of cell lysis.
  • Channels with 1-D apertures may be strategically arranged in an array according to "effusive filtration" configuration as described in US Patent No. 2008/0318324 to further re-direct, partition, dampen, or disperse the flow, consequently reducing the force of impact experienced by the cells at the moment of exclusion.
  • the walls that enclose the flow channel may be fabricated using a UV-curing process in accordance with the procedures described in PCT PCT/US2009/02426 , from a biocompatible substrate material that is a medical-device grade polymer, so that the eDAR apparatus would be in compliance with regulations governing medical device manufacturing.
  • the mechanism for directing the flow directs the flow of the aliquot into either a first exit channel if the aliquot contains a rare particle or a second exit channel if the aliquot does not contain a rare particle.
  • the mechanism for directing the flow directs the flow of an aliquot containing a rare particle into one of a plurality of exit channels depending on the identity, composition, or quantity of the rare particle.
  • the mechanism for directing the flow of the aliquot comprises an electrode, a magnetic element, an acoustic element, an electro-actuated element, an electric field, or a magnetic field.
  • the mechanism for directing the flow of the aliquot comprises one or more electro-actuated valves or pistons, wherein the valves or pistons control the flow of a liquid in at least a first directional flow channel that intersects with the first input channel and the two exit channels at a first junction.
  • solenoid pistons are subcomponents of electro-actuated solenoid valves.
  • solenoid pistons are embedded in device by molding.
  • the embedded solenoid pistons may be replaced by solenoid valves in fluidic communication via tubings.
  • an apparatus provided herein may comprise one or more electrodes for tracking and/or manipulating the trajectory or flow of a particle, aliquot, or fluid sample.
  • the electrode may enhance the separation of an aliquot based on phenomena such dielectrophoresis or electrowetting.
  • the apparatuses of the present invention may comprise one or more acoustical elements for tracking and/or manipulating the trajectory or flow of a particle, aliquot, or fluid sample.
  • acoustical elements may be used to manipulate the trajectory of select particles or cells with acoustical energy (e.g ., acoustophoresis, ultrasonic or megasonic waves) to improve cell separation based on the response of cells to compressive pressure waves.
  • the apparatuses provided herein may further comprise a magnetic element for the separation of a rare particle or cell bound to or bound by a magnetic particle.
  • the magnetic element may enhance the separation of an aliquot, particle, or cell based on the magnetic susceptibility of the cells or the micro-magnetic or nano-magnetic particles attached to a particle or cell.
  • an apparatus provided herein may comprises the use of fluidic pressure changes, flow-rate changes, or electroosmostic flow changes to manipulate the trajectory of select particles or cells.
  • the detector is selected from the group consisting of a camera, an electron multiplier, a charge-coupled device (CCD) image sensor, a photomultiplier tube (PMT), an avalanche photodiode (APD), a single-photon avalanche diode (SPAD), and a complementary metal oxide semiconductor (CMOS) image sensor.
  • a camera an electron multiplier, a charge-coupled device (CCD) image sensor, a photomultiplier tube (PMT), an avalanche photodiode (APD), a single-photon avalanche diode (SPAD), and a complementary metal oxide semiconductor (CMOS) image sensor.
  • CCD charge-coupled device
  • PMT photomultiplier tube
  • APD avalanche photodiode
  • SPAD single-photon avalanche diode
  • CMOS complementary metal oxide semiconductor
  • an apparatus provided herein may comprise a photo, electro, acoustical or magnetic detector to track the motion of select cells or to enumerate select particles or cells present in an aliquot.
  • an apparatus or method provided herein may incorporate fluorescence (single or multi-color) microscopy imaging in various configurations, which include but are not limited to bright-field, epi, confocal, DIC (differential interference contrast), dark-field, Hoffinan, or phase-contrast.
  • fluorescence single or multi-color microscopy imaging in various configurations, which include but are not limited to bright-field, epi, confocal, DIC (differential interference contrast), dark-field, Hoffinan, or phase-contrast.
  • the apparatuses provided herein may comprise a plurality of detection devices, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more detection devices. Multiple detection devices may be necessary for performing a methods of the present invention, for example, wherein more than one rare particle or cell is present in a fluid sample, more than one cell marker is being used to differentiate different cell types, or multiple detection reagents are being detected simultaneously.
  • the apparatuses provided herein may further comprise a source for interrogating or exciting a detectable moiety present in an aliquot.
  • the source for interrogating is selected from, for example, a laser (solid state, diode-pumped, ion, or dye), a light-emitting diode (LED), a lamp, an arc discharge, a magnetic pulse, or a natural light source.
  • the apparatuses provided herein may comprise a plurality of interrogation devices, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more detection devices. Multiple interrogation devices may be necessary for performing a methods of the present invention, for example, wherein more than one rare particle or cell is present in a fluid sample, more than one cell marker is being used to differentiate different cell types, or multiple detection reagents are being detected simultaneously.
  • a ranking device may be selected from a computer, a controller, a chip with integrated circuits, a circuit board, an electronic element, software, an algorithm, or a combination thereof
  • an apparatus provided herein may comprise a plurality of flow channels, including one or more input flow channels (i.e., channels that bring an aliquot to a detection volume) and one or more output channels ( i.e., channels that take an aliquot away from a detection volume.
  • an apparatus as provided herein may comprise a combination of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more input channels and at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more output channels.
  • an apparatus may comprise multiple flow channels connecting to the main channel to inject additional fluid to alter the local velocity.
  • an apparatus provided herein may comprise a flow channel or chamber enclosed by walls fabricated from materials including, but not limited to, polymeric materials (polydimethylsiloxane (PDMS), polyurethane-methacrylate (PUMA), polymethylmethacrylate (PMMA), polyethylene, polyester (PET), polytetrafluoroethylene (PTFE), polycarbonate, parylene, polyvinyl chloride, fluoroethylpropylene, lexan, polystyrene, cyclic olefin copolymers, polyurethane, polyestercarbonate, polypropylene, polybutylene, polyacrylate, polycaprolactone, polyketone, polyphthalamide, cellulose acetate, polyacrylonitrile, polysulfone, epoxy polymers, thermoplastics, fluoropolymer, and polyvinylidene fluoride, polyamide, polyimide), inorganic materials (glass, quartz, silicon, GaAs, silicon nitride), fused si
  • a wall materials can be fabricated of porous membranes, woven or non-woven fibers (such as cloth or mesh) of wool, metal (e.g. stainless steel or Monel), glass, paper, or synthetic (e.g. nylon, polypropylene, polycarbonate, parylene, and various polyesters), sintered stainless steel and other metals, and porous inorganic materials such as alumina, silica or carbon.
  • the apparatuses provided herein may comprise a flow channel or chamber that has been pre-treated with a chemical or biological molecule.
  • a channel or chamber may be treated with an anticoagulant compound to prevent or reduce the association of a particle in the fluid sample, a compound that preferentially binds to a particle in the fluid sample, for example a rare particle or cell, or a compound that prevents or reduces the agglomeration or aggregation of a particle in the fluid sample.
  • the channel or chamber surfaces may be treated with anticoagulant compounds, compounds that preferentially bind to circulating tumor cells, or compounds that prevent the sticking of cells.
  • a channel or chamber surface may be modified chemically to enhance wetting or to assist in the adsorption of select cells, particles, or molecules.
  • Surface-modification chemicals may include but not limited to silanes such as trimethylchlorosilane (TMCS), hexamethyldisilazane (HMDS), (Tridecafluoro-1,1,2,2-tetrahydrooctyl)trichlorosilane, chlorodimethyloctylsilane, Octadecyltrichlorosilane (OTS) or ⁇ -methyacryloxypropyltrimethyoxy-silane; polymers such as acrylic acid, acrylamide, dimethylacrylamide (DMA), 2-hydroxyethyl acrylate, polyvinylalcohol (PVA), poly(vinylpyrrolidone (PVP), poly(ethylene imine) (PEI), Polyethylene glycol (PEG), epoxy poly(dimethylacrylamide (EPDMA), or PEG-mon
  • the apparatuses provided herein may further comprise a means for reducing excessive background signal and/or improving the signal-to-noise ratio.
  • a means for reducing excessive background signal and increasing the signal-to-noise ratio the sensitivity of detection is enhanced as the weak signals from even a highly diluted aliquot can be accurately detected.
  • the better the signal-to-noise ratio larger an aliquot can be scanned.
  • the fluidic throughput is correspondingly increased since fewer (but larger) aliquots need to be scanned.
  • the means for reducing background signal comprises a mask.
  • a mask can consist of any number of apertures of any shape or size, positioned in any orientation with or without any periodic spacing.
  • FIG 3 illustrates a mask (301) containing an array of apertures (311), positioned between the detection volume and a detector to selectively allow through a detectable characteristic.
  • a mask may comprise an optical element that selectively pass through certain wavelengths of light, for example, a low-pass, high-pass, or band-pass filter, or acousto-optic modulator, spatial-light modulator, light-chopper, fabricated hologram, physical aperture, or galvo scanner.
  • a low-pass, high-pass, or band-pass filter or acousto-optic modulator, spatial-light modulator, light-chopper, fabricated hologram, physical aperture, or galvo scanner.
  • a mask can consist of magnetic elements that selectively prevent passage of a magnetic field.
  • a device selected from a lock-in amplifier, a scanning detector, a modulated interrogator or detector, or any apparatuses that modulate frequency or intensity may be used to increase the signal-to-noise ratio.
  • detectors with spatial-modulation functionality of a mask directly incorporated within may be used in conjunction with the apparatuses provided herein.
  • a separate mask is not present.
  • a separate mask is also present.
  • Non-limiting examples of detectors with incorporated mask functionality include photodiode arrays or cameras with spatial pixelation such that signals of individual photodiodes or select pixels of cameras may be removed or kept.
  • the apparatuses provided herein may further comprise additional elements useful for performing assays, processes, or tests in a fashion that is coupled to the eDAR methods provided herein.
  • an apparatus provided herein may further comprise one or more resistive heating elements to perform on-chip cellular assays such as Polymerase Chain Reaction (PCR) or Real-Time Polymerase Chain Reaction (RT-PCR).
  • PCR Polymerase Chain Reaction
  • RT-PCR Real-Time Polymerase Chain Reaction
  • an apparatus provided herein may further comprises one or more electrodes, for example, to conduct on-chip chemical assay such as electrophoresis or eletrochromatography.
  • an apparatus provided herein may further comprise a filter element.
  • the filter element may be in the form of microposts, microimpactors, microsieves, channels with apertures smaller than bioparticles, channels with apertures such that a bioparticle is prevented from entering an apertured but fluid is allowed to continue to flow around the bioparticle through the aperture ("1-D channels"), microbeads, porous membranes, protrusions from the walls, adhesive coating, woven or non-woven fibers (such as cloth or mesh) of wool, metal (e.g. stainless steel or Monel), glass, paper, or synthetic (e.g. nylon, polypropylene, polycarbonate, parylene, and polyester), sintered stainless steel or other metals, or porous inorganic materials such as alumina, silica, or carbon.
  • Figure 16 illustrates a filter element (1622), which may be disposed in a channel, such as an outlet channel (1621), to selectively allow the passage of fluid portion while retaining the desired bioparticles.
  • an apparatus provided herein may be coupled to a conventional flow cytometer.
  • Figure 16 illustrates an outlet channel (1621) that may be in fluidic communication to a conventional flow cytometer (with or without filter element 1622) such that discrete aliquot 1661 containing rare cell 1602 is further examined or sorted serially (one cell by one cell).
  • An example of an eDAR apparatus with a single inlet and outlet port for the detection or quantitation of rare particles in a fluid is shown.
  • Figure 4 shows an example of eDAR apparatus consisting of a device (411) to aliquot a cell suspension, an interrogation device (421 and 422), a detection or imaging device (431, 432, and 433), and a ranking device (computer not shown).
  • a device (411) to aliquot a cell suspension may consist of a fluidic channel (414) contained within walls and fluidic ports (412 and 413).
  • a laser serves as an interrogation device.
  • An inverted microscope with photodiodes, photomultipliers, or cameras is used as a detection device.
  • a mask (451) is placed in a path between the channel (414) and the detection devices (431, 432, and 433).
  • a computer accepts the signal from the detection device and through an algorithm ranks the aliquot. The computer then directs the aliquot into the proper channel based on the value of the ranking (i.e., the presence, absence, quantity, identity, or composition of rare particles in the fluid sample).
  • Figure 4 illustrates three detection devices (431, 432, and 433) and two interrogation devices (421 and 422), in practice eDAR may consist of only one detection device and one interrogation device, or multitudes of detection devices and interrogation devices.
  • the interrogation devices (421 and 422) consisted of a 488 nm solid-state diode pumped laser and a 633 nm HeNe laser which are directed into an inverted microscope.
  • the two laser beams were shaped using cylindrical optics to form a collimated elliptical beam with an aspect ratio of 10 to 1 prior to entering the microscope objective.
  • the intensity of each beam could be adjusted, while mirrors independently steered the light to create a spatially co-localized excitation region.
  • the fluorescence from bioparticles was split into three wavelength bands by two dichroic mirrors before passing through the bandpass filters and refocused onto the three single-photon avalanche diodes (SPADs; 431, 432, and 433).
  • One SPAD collected fluorescence in the wavelength range of 560-610 nm a second SPAD collected fluorescence in the range of 645-700 nm, and a third SPAD collected in the range of 500-540 nm.
  • the SPAD outputs were directed to a computer with a counter/timer board and analyzed with several algorithms.
  • eDAR apparatus with two outlet ports for the detection or quantitation of rare particles in a fluid.
  • FIG. 5 illustrates an eDAR apparatus consisting of a device to aliquot cell suspension (510), an interrogation device (521), a detection or imaging device (531), a ranking device (computer not shown), and an apparatus to direct aliquot according to the assigned ranking.
  • This apparatus also includes a single inlet port (511), two outlet ports (512 and 513), and three fluidic channels (514) joined at a single point to aliquot the fluid.
  • a laser serves as the interrogation device (521) and an inverted microscope with photodiodes, photomultipliers, or cameras serves as detection device (531).
  • a mask (551) is placed between the channels (514) and the detection device (531).
  • a computer accepts the signal from the detection device and ranks the aliquot through an algorithm.
  • the device then utilizes an electrical, magnetic, hydrodynamic, or pneumatic mean to direct the aliquot into either outlet 512 or outlet 513 according to the assigned ranking.
  • FIG. 6 illustrates an eDAR apparatus with one interrogation device (640) and three detection devices (650, 651, and 652).
  • eDAR apparatus with multiple inlet and/or outlet ports for the detection or quantitation of rare particles in a fluid.
  • an eDAR apparatus may consist of multiple inlet and/or outlet ports.
  • Figure 7 illustrates a device (710) to aliquot suspension with five ports (711, 712, 713, 714, and 715) and five fluidic channels 716 joined at a single point.
  • One or more ports may be used as fluidic inlet; one or more ports may be used as fluidic outlet.
  • the apparatus may be used such that two ports are used as inlet ports and three ports are used as outlet ports, or it may be used such that one port is an inlet port and four ports are outlet ports, etc.
  • the device (710) may contain any number of fluidic inlets and outlets and any number of fluidic channels. These fluidic channels may be joined at more than one point and the joining point need not be circumscribed by the fluidic inlets or outlets.
  • CTCs circulating tumor cells
  • Freshly venipunctured blood from Stage IV metastatic breast cancer patients was drawn from a single puncture into three separate tubes.
  • the first blood portion (first tube) was discarded to avoid possible contamination of epithelial cells from skin puncture.
  • a second portion was collected into Veridex's CellSave tube containing stabilizing reagents for circulating tumor cell detection using a Veridex's CellSearch system.
  • a third portion was collected into a collection tube containing EDTA anticoagulant for separate analysis using eDAR.
  • the third portion was incubated with enzymes, fixatives, permeability reagents, and fluorescent antibodies targeting pan-cytokeratin, CD45, and Epithelial Cell Adhesion Molecule (EpCAM).
  • a positive identification of circulating tumor cell is defined as a cell expressing pan-cytokeratin and EpCAM, but not CD45.
  • CD45 is commonly known as leucocyte common antigen and is indicative of a white blood cell. An object bound with all three antibodies is deemed false-positive, frequently a result of protein aggregation.
  • the 5 to 10 mL antibody-labeled blood samples were flowed through an eDAR apparatus as described in Example 1 at a flow rate of between about 10-500 ⁇ L/min, using a compressed air source supplying 7.6 psi to drive the flow.
  • the eDAR apparatus was operating in the continuous flow (simultaneous) mode.
  • microchannels that were 200 ⁇ m wide by 50 ⁇ m tall were used.
  • line-confocal excitation beams were provided at both 488 nm and 633 nm, which illuminated a sheet of light that was about 5-10 ⁇ m thin.
  • the line-confocal detection volume had dimensions of about 200 ⁇ m (width) ⁇ 50 ⁇ m (height) ⁇ 10 ⁇ m (thickness), providing a detection volume of about 0.1 nL.
  • Three SPAD detection devices were operating at 10,000 Hz sampling rate, configured to detect fluorescence signals emanating from the cells at 450-610 nm, 645-700 nm, and 500-540 nm. At this rate, each aliquot was on the order of 1 nL to 50 nL, estimated to contain 5-250 white blood cells and 5,000-25,000 red blood cells. For a sample of 5-10 mL, it thus takes between 10-20 min to process the sample at a flow rate of 500 ⁇ L/min. A 5 mL sample processed in this fashion will be divided into 10,000 aliquots having a volume of 50 nL each.
  • a 5 mL sample containing 200 CTCs can be reduced to a volume of 10 ⁇ L in only 10 minutes, without the use of a filter. If the eDAR apparatus was further in liquid contact with a flow cytometer, All of the 200 CTC cells present in the 5 mL sample could be counted and/or individually isolated in only 2% of the normal time by implementing an eDAR step prior to the flow cytometry.
  • FIG. 8 shows CTC counts from 27 blood samples from Stage IV breast cancer patients (of multiple patients drawn on different dates) using Veridex's CellSearch system (lower panel) and eDAR (upper panel).
  • Veridex's CellSearch system lower panel
  • eDAR upper panel
  • most patient samples registered zero CTC counts using CellSearch system.
  • more than 50% of the same patient blood draws analyzed by eDAR were found to contain 200-400 CTC counts.
  • This amply demonstrates a hundred times more sensitivity with the use of eDAR, as compared to the use of Veridex's commercial CellSearch system.
  • the heightened sensitivity of eDAR is attributable to accurate discrimination between CTCs and background by aliquot ranking and the use of a mask.
  • FIG 9 Exemplary images of a CTC detected by this eDAR method are provided in Figure 9 .
  • FIG 9A is a brightfield image of a CTC amidst red blood cells.
  • FIG 9B is a fluorescence image indicating the presence of pan-cytokeratin.
  • FIG 9C is a fluorescence image indicating the absence of CD45, hence ruling out the possibility of false-identifying a white blood cell as a CTC.
  • Cancer cells segregated by eDAR may be further analyzed to distinguish the subpopulations within the biological fluid.
  • some cancer cells may be distinguished from others.
  • cancer cells that express CD44 but not CD24 proteins have recently been called cancer stem cells for their association with high metastatic potential.
  • Other proteins may be associated with various traits of cells.
  • FIG 10 demonstrates the identification of breast cancer stem cells (marked with arrowheads).
  • breast cancer cells MCF-7 were labeled with Alexa 488-anti-CD44 (positive) and Alexa 647-anti-CD24 (negative).
  • FIG 10A is a fluorescence image (500-540 nm) for detecting Alexa 488-anti-CD44 (green);
  • FIG 10B is a fluorescence image (645-700 nm) for detecting Alexa 647-anti-CD24 (red);
  • FIG 10C is the brightfield image.
  • FIG 10D is a composite image indicating CD44+/CD24- (arrows indicate cancer stem cells). Approximately 25% of cancer cells were found to express CD44 but not CD24 and thus meet the criteria for cancer stem cells. In this fashion, eDAR may be used to distinguish subpopulations of cancer cells in a biological fluid.
  • eDAR may operated by using discrete aqueous aliquots that are separated by an immiscible phase to encapsulate bioparticles prior to the detection step.
  • Figure 16 illustrates an eDAR apparatus operating in this fashion.
  • a cell suspension containing undesired cells (1601) and desired rare cells 1602 is partitioned into discrete aliquots (1631, 1641, 1651, and 1661), which are separated from one another by an immiscible phase (1642).
  • the discrete aliquots are directed to flow from let to right in a flow channel (1603).
  • aliquot 1641 traverses the detection volume (1604; cylindrical outline), multiple cells encapsulated within the discrete aliquot (1641) are detected simultaneously. If no desired cells are detected, the discrete aliquot (1641) is ranked as null and directed toward Channel 1611 ( see, for example, aliquot 1651). If any desired rare cells are detected, the discrete aliquot is ranked as nonzero and is directed toward Channel 1621 ( see, for example, aliquot 1661).
  • filter element 1622 may be disposed in channel 1621 to selectively allow the passage of fluid portion while retaining the desired bioparticles.
  • and eDAR apparatus may be coupled to a conventional flow cytometer.
  • channel 1621 may be in fluidic communication to a conventional flow cytometer (with or without filter element 1622), such that discrete aliquot 1661 containing rare cell 1602 is further examined or sorted serially (one cell at a time).
  • the immiscible phase (1642) may be continuous ( i.e., surrounds the discrete aliquots entirely) as illustrated in Figure 16 or segmented ( i.e., immiscible phase 1642 occupies only the spacing between discrete aliquots but does not completely surround the aliquots).
  • a 10-mL cell suspension contains only 9 desired rare cells amidst 10 billion undesired cells, eDAR, in the simplest form, would require the detection of a characteristic from the desired cells contained in 10 aliquots. Since there are only 9 desired cells, at least one aliquot would be devoid of the desired cells and can be ranked as null and discarded immediately. The undesired cells contained in the discarded portion would not need to be screened individually. Consequently, with merely 10 aliquots at least 1/10 of total volumes is immediately discarded and 1/10 of the undesired cells (contained within the discarded volume) would not need to be detected individually.
  • Figure 1 illustrates a particular embodiment of the invention, wherein a rare particle characteristic is detected in an aliquot during operation of a simultaneous mode.
  • a cell suspension containing undesirable cells (101) and desirable rare cells (102) is directed to flow from left to right in a flow channel (103).
  • Multiple cells may traverse a detection volume (104) enclosed by a shaded cylinder at a given time and be detected simultaneously. If no desired cells are detected, an aliquot equivalent to the detection volume is ranked as null and directed toward Channel 111. If any desired cells are detected, the aliquot is ranked as nonzero and is directed toward Channel 121.
  • a filter element (122) may optionally be disposed in Channel 121 to selectively allow the passage of the fluid portion while retaining the desired bioparticles.
  • the filter element may be in the form of microposts, microimpactors, microsieves, channels with apertures smaller than bioparticles, channels with apertures such that a bioparticle is prevented from entering an aperture but fluid is allowed to continue to flow around the bioparticle through the aperture ("1-D channels"), microbeads, porous membranes, protrusions from the walls, adhesive coating, woven or non-woven fibers (such as cloth or mesh) of wool, metal (e.g. stainless steel or Monel), glass, paper, or synthetic (e.g. nylon, polypropylene, polycarbonate, parylene, and polyester), sintered stainless steel or other metals, or porous inorganic materials such as alumina, silica, or carbon.
  • the method may further consist of selectively masking the aliquot as to reduce excessive background signal and improve the signal-to-noise ratio.
  • FIG 2 illustrates the use of a mask (211) with an array of apertures (212) positioned between the detection volume and a detector to selectively allow through a detectable characteristic. Multiple bioparticles still can be simultaneously detected with the use of the mask (211).
  • the fluidic throughput is correspondingly increased since fewer (but larger) aliquots need to be scanned. If no desired bioparticles are detected, an aliquot equivalent to the detection volume is ranked as null and directed toward Channel 221. If any desired bioparticles are detected, the aliquot is ranked as nonzero and is directed toward Channel 222.
  • FIG 11 panel A which is an enlarged illustration of device 710 ( FIG 7 ), illustrates device 1110, for aliquoting suspension with five fluidic channels (1111, 1112, 1113, 1114, and 1115) joined at junction 1116.
  • Fluidic channels 1111, 1112, 1113 carried fluid toward junction 1116, whereas fluidic channels 1114 and 1115 carried fluid away from junction 1116.
  • Solenoid piston 1120 was placed on top of channel 1111 and solenoid piston 1121 was placed on top of channel 1112.
  • Solenoid pistons 1120 and 1121 were configured to push down on an elastomeric polydimethylsiloxane (PDMS) membrane, which separated the pistons 1120 and 1121 from the fluid in the channels 1111 and 1112.
  • PDMS elastomeric polydimethylsiloxane
  • FIG 11 panel A illustrates the operation of device 1110 for aliquoting suspension.
  • solenoid piston 1120 pushing down on the PDMS membrane on top of flow channel 1111, channel 1111 was closed off.
  • solenoid piston 1121 was configured to allow fluid to pass through channel 1112 toward junction 1116.
  • blood containing rare cells in the incoming channel 1112 was diverted to left outlet channel 1114 (see panel B, 0 ms).
  • solenoid piston 1120 was retracted from the PDMS membrane on top of channel 1111 while solenoid piston 1121 pushed down the PDMS membrane on top of channel 1112.
  • FIG 12 panel A illustrates device 1210 used for aliquoting suspension with five fluidic channels (1211, 1212, 1213, 1214, and 1215) joined at junction 1240.
  • Fluidic channels 1211, 1212, and 1213 carried fluid toward junction 1240, whereas fluidic channels 1214 and 1215 carried fluid away from junction 1240.
  • Solenoid valve 1220 was connected to port 1216 in fluidic communication with channel 1211 via tubing 1221, and solenoid valve 1222 was connected to port 1217 in fluidic communication with channel 1212 via tubing 1223.
  • Solenoid valves 1220 and 1222 was actuated to close or open with electronic or computer signal (e.g. TTL signal).
  • electronic or computer signal e.g. TTL signal.
  • solenoid valve 1220 was closed while solenoid valve 1222 remained open, aliquot 1260 of blood containing rare cells in the incoming channel 1213 was diverted to the left outlet channel 1214 (see panel B, 0 ms).
  • solenoid valve 1220 was opened while solenoid valve 1222 remained closed, aliquot 1260 of blood containing rare cells in the incoming channel 1213 was diverted to the right outlet channel 1215 (see panel C, 2 ms). Aliquot redirecting using a combination of solenoid valves 1220 and 1222 could channel the aliquot from one channel to another in as little as 2 ms.
  • a mixture of blood and cancer cells was prepared according to the following procedure: 1x10E6/mL MCF-7 cells were labeled with 20 ⁇ L of fluorescent EpCAM antibody. This cell mixture was then diluted to 1x10E5 cells/mL with Isoton hematological diluent. Ten ⁇ L of the diluted cell mixture was then added to 2 mL of whole human blood and flowed through the aliquoting device. The flow rate in the aliquoting device was nominally 30 ⁇ L/min unless otherwise indicated.
  • FIG 13 shows the fluorescence signals collected from 2 avalanche photodiodes (APDs) positioned at different locations upstream and downstream of junction 1116 (or 1240).
  • Plot 1310 shows the signal trace 1311 from one APD configured to detect the presence of EpCAM molecule in an aliquot at detection volume 1140 (or 1270), whereas Plot 1320 shows the signal trace 1321 from a second APD configured to detect the presence of EpCAM molecule in channel 1114 (or 1214).
  • the signal peaks 1312 matched substantially the signal peaks 1322, indicating that channeling of aliquot was correct, resulting in a high recovery of rare cells.
  • FIG 14 Plot 1410 shows the percentage of cancer cells recovered as a function of the pulse length.
  • Trace 1420 indicates that when the pulse width was 10 ms or below, 100% of the cancer cells were collected in the correct channel. As pulse width increased, trace 1420 decreased, indicating a loss of cells to the wrong channel.
  • FIG 15 shows plot 1510 with trace 1520 indicating the percentage of rare cells recovered as a function of incoming flow rate.
  • the flow rate was below 30 ⁇ L/min, the recovery was between 89-100%.
  • the flow rate increased, the recovery decreased, indicating an increasing loss of rare cells in the wrong channel.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Electromagnetism (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EP15188512.6A 2009-04-13 2010-04-13 Rare particle detection method and apparatus Active EP2990795B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP17187038.9A EP3299812B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and apparatus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16889209P 2009-04-13 2009-04-13
EP10765047.5A EP2419726B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and aparatus

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP10765047.5A Division EP2419726B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and aparatus
EP10765047.5A Division-Into EP2419726B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and aparatus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP17187038.9A Division EP3299812B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and apparatus

Publications (2)

Publication Number Publication Date
EP2990795A1 EP2990795A1 (en) 2016-03-02
EP2990795B1 true EP2990795B1 (en) 2017-08-23

Family

ID=42983110

Family Applications (3)

Application Number Title Priority Date Filing Date
EP17187038.9A Active EP3299812B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and apparatus
EP10765047.5A Active EP2419726B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and aparatus
EP15188512.6A Active EP2990795B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and apparatus

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP17187038.9A Active EP3299812B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and apparatus
EP10765047.5A Active EP2419726B1 (en) 2009-04-13 2010-04-13 Rare particle detection method and aparatus

Country Status (9)

Country Link
US (2) US20120129190A1 (zh)
EP (3) EP3299812B1 (zh)
JP (3) JP5734274B2 (zh)
KR (1) KR101893613B1 (zh)
CN (2) CN105242004B (zh)
AU (2) AU2010236572B2 (zh)
CA (1) CA2758382C (zh)
ES (1) ES2638861T3 (zh)
WO (1) WO2010120818A2 (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2638861T3 (es) 2009-04-13 2017-10-24 University Of Washington Método y aparato de detección de partículas raras
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
BR112013024190A2 (pt) 2011-03-24 2016-12-13 Anpac Bio Medical Science Co Ltd microdispositivo para detectar ou tratar doença e métodos para fabricar microdispositivo e para detectar doença em indivíduo em necessidade do mesmo
US20140073884A1 (en) * 2011-05-05 2014-03-13 Anpac Bio-Medical Science Co., Ltd. Apparatus for detecting tumor cells
EP3928715A1 (en) 2011-06-19 2021-12-29 DNA Genotek, Inc. Devices, solutions and methods for sample collection
US9174216B2 (en) 2013-03-13 2015-11-03 DeNovo Science, Inc. System for capturing and analyzing cells
US9404864B2 (en) 2013-03-13 2016-08-02 Denovo Sciences, Inc. System for imaging captured cells
US10466160B2 (en) 2011-08-01 2019-11-05 Celsee Diagnostics, Inc. System and method for retrieving and analyzing particles
CA2842359A1 (en) 2011-08-01 2013-02-07 Denovo Sciences Cell capture system and method of use
WO2014097991A1 (ja) * 2012-12-18 2014-06-26 コニカミノルタ株式会社 希少細胞検出装置、希少細胞検出方法、希少細胞観察システム、および細胞展開用デバイス
KR101433189B1 (ko) * 2013-01-18 2014-08-28 연세대학교 산학협력단 광학 센서 및 영상 생성 방법
US9752181B2 (en) 2013-01-26 2017-09-05 Denovo Sciences, Inc. System and method for capturing and analyzing cells
US9707562B2 (en) 2013-03-13 2017-07-18 Denovo Sciences, Inc. System for capturing and analyzing cells
KR101412777B1 (ko) * 2013-03-29 2014-07-01 성원기 다성분 동시 정량 분석용 측방 유동 디바이스
US10391490B2 (en) 2013-05-31 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
US9856535B2 (en) 2013-05-31 2018-01-02 Denovo Sciences, Inc. System for isolating cells
EP3017308A4 (en) * 2013-07-05 2017-04-26 University Of Washington Through Its Center For Commercialization Methods, compositions and systems for microfluidic assays
US8820538B1 (en) * 2014-03-17 2014-09-02 Namocell LLC Method and apparatus for particle sorting
KR101528773B1 (ko) * 2014-05-16 2015-06-15 연세대학교 산학협력단 대기중의 바이오 입자 및 넌바이오 입자 실시간 검출장치 및 이를 이용한 검출방법
WO2016013041A1 (ja) * 2014-07-22 2016-01-28 株式会社がん免疫研究所 末梢循環癌細胞の検出方法および検出装置
AU2015307593B2 (en) 2014-08-28 2017-04-13 Sysmex Corporation Particle imaging apparatus and particle imaging method
US20170258369A1 (en) * 2014-11-19 2017-09-14 The University Of Toledo Laryngeal mechanosensor stimulator
WO2016121574A1 (ja) * 2015-01-29 2016-08-04 コニカミノルタ株式会社 相互作用する分子を有する血中細胞の同時検出方法
JP7344631B2 (ja) * 2015-02-09 2023-09-14 アボゲン， インコーポレイティド サンプル収集関連応用、分析および診断のためのデバイス、溶液および方法
WO2016161109A1 (en) 2015-03-31 2016-10-06 The Regents Of The University Of California System and method for tunable patterning and assembly of particles via acoustophoresis
EP3294415A4 (en) * 2015-05-14 2018-12-05 The Board of Trustees of the University of Illionis Method for monitoring efficacy of a cancer therapy using circulating tumor cells as a biomarker
US10839509B2 (en) 2015-07-10 2020-11-17 3Scan Inc. Spatial multiplexing of histological stains
US9757728B2 (en) * 2016-01-26 2017-09-12 Lidong Qin Microfluidic aliquoting for single-cell isolation
CN106872339A (zh) * 2017-01-10 2017-06-20 中国科学院苏州生物医学工程技术研究所 一种粒子排序方法及其装置和用途
JP6786039B2 (ja) * 2017-03-03 2020-11-18 国立大学法人 熊本大学 光学測定システム、光学セル及び光学測定方法
JP6842168B2 (ja) * 2017-05-12 2021-03-17 国立大学法人東北大学 マイクロ水滴内イムノアッセイ
EP3669166B1 (en) * 2017-08-15 2024-07-03 The University of Washington Particle separation systems and methods
US10391493B2 (en) 2017-08-29 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
JP6871116B2 (ja) * 2017-09-15 2021-05-12 株式会社東芝 セルソータ
CN111433350B (zh) * 2017-11-30 2023-11-14 烟台澳斯邦生物工程有限公司 从生物样品分离颗粒的方法、系统和过滤单元
WO2019119368A1 (zh) * 2017-12-21 2019-06-27 深圳先进技术研究院 一种声驱动的流式细胞检测装置
US11022538B2 (en) 2018-05-15 2021-06-01 Government Of The United States Of America, As Represented By The Secretary Of Commerce Quantum flow cytometer
JP2020134341A (ja) * 2019-02-20 2020-08-31 シスメックス株式会社 測定成否判定方法および試料測定装置
US10633693B1 (en) 2019-04-16 2020-04-28 Celsee Diagnostics, Inc. System and method for leakage control in a particle capture system
AU2020262398A1 (en) * 2019-04-24 2021-11-04 Bennubio Inc. Positionally assisted negative particle rejection (PANR) to sort and enrich target cells of interest
US11273439B2 (en) 2019-05-07 2022-03-15 Bio-Rad Laboratories, Inc. System and method for target material retrieval from microwells
JP7413408B2 (ja) 2019-05-07 2024-01-15 バイオ－ラッド ラボラトリーズ インコーポレイテッド 自動化された単一細胞処理のためのシステムおよび方法
CA3143241A1 (en) 2019-06-14 2020-12-17 Bio-Rad Laboratories, Inc. System and method for automated single cell processing and analyses
US20210237064A1 (en) * 2020-01-31 2021-08-05 Astrin Biosciences, Inc. Biological Fluid Filtration System
US11504719B2 (en) 2020-03-12 2022-11-22 Bio-Rad Laboratories, Inc. System and method for receiving and delivering a fluid for sample processing
US20220003731A1 (en) * 2020-07-06 2022-01-06 Florida Atlantic University Board Of Trustees Vascular occlusion testing device
CN113125402B (zh) * 2021-04-22 2022-09-23 中国科学院水生生物研究所 一种样品支持与分选芯片及流体进样分选系统

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6182168A (ja) 1984-09-28 1986-04-25 Shimadzu Corp 生化学分析の方法
US5602042A (en) * 1994-04-14 1997-02-11 Cytyc Corporation Method and apparatus for magnetically separating biological particles from a mixture
DE19709348C2 (de) 1996-05-29 1999-07-01 Schubert Walter Dr Md Automatisches Multi-Epitop-Ligand-Kartierungsverfahren
US6365362B1 (en) 1998-02-12 2002-04-02 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US7351376B1 (en) 2000-06-05 2008-04-01 California Institute Of Technology Integrated active flux microfluidic devices and methods
WO2002023163A1 (en) 2000-09-15 2002-03-21 California Institute Of Technology Microfabricated crossflow devices and methods
US6933109B2 (en) * 2000-12-22 2005-08-23 Large Scale Proteomics Corporation Rapid particle detection
EP1399580B1 (en) * 2001-05-26 2008-10-08 One Cell Systems, Inc. Secretion of proteins by encapsulated cells
US7252987B2 (en) * 2001-12-06 2007-08-07 Islet Technology, Inc. System for analysis and selection of encapsulated cellular materials
US20030133119A1 (en) * 2002-01-17 2003-07-17 Bachur Nicholas R. Rapid imaging of particles in a large fluid volume through flow cell imaging
US20030175980A1 (en) * 2002-03-14 2003-09-18 Hayenga Jon W. Ribbon flow cytometry and cell sorting
US7312085B2 (en) 2002-04-01 2007-12-25 Fluidigm Corporation Microfluidic particle-analysis systems
US6808075B2 (en) * 2002-04-17 2004-10-26 Cytonome, Inc. Method and apparatus for sorting particles
EP2282214B1 (en) 2002-05-09 2022-10-05 The University of Chicago Device and method for pressure-driven plug transport and reaction
KR100990016B1 (ko) 2002-09-16 2010-10-26 사이토놈/에스티, 엘엘씨 입자 선별 방법 및 장치
TW574130B (en) 2003-06-02 2004-02-01 Hsien-Chang Chang An innovative micro-fabrication for electroosmotic flow (EOF) control via a self-assembled monolayer by using a perpendicular electric potential
CA2536360C (en) * 2003-08-28 2013-08-06 Celula, Inc. Methods and apparatus for sorting cells using an optical switch in a microfluidic channel network
US20050103690A1 (en) * 2003-11-19 2005-05-19 Aisin Seiki Kabushiki Kaisha Micro liquid control system
JP2005245317A (ja) * 2004-03-04 2005-09-15 Mitsubishi Electric Corp 微生物の計測装置及び計測方法
US20050221339A1 (en) * 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) * 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
CN101087655A (zh) * 2004-12-23 2007-12-12 皇家飞利浦电子股份有限公司 通过诱导电流变或磁流变效应控制含生物材料液体流动的方法
ES2404311T3 (es) 2005-04-12 2013-05-27 454 Life Sciences Corporation Métodos para determinar variantes de secuencias usando secuenciación ultraprofunda
US7846743B2 (en) 2005-04-21 2010-12-07 California Institute Of Technology Uses of parylene membrane filters
US7993821B2 (en) 2005-08-11 2011-08-09 University Of Washington Methods and apparatus for the isolation and enrichment of circulating tumor cells
US8173413B2 (en) 2005-08-11 2012-05-08 University Of Washington Separation and concentration of biological cells and biological particles using a one-dimensional channel
EP1984738A2 (en) * 2006-01-11 2008-10-29 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
EP2481815B1 (en) * 2006-05-11 2016-01-27 Raindance Technologies, Inc. Microfluidic devices
US7790118B2 (en) * 2006-10-18 2010-09-07 California Institute Of Technology Microfluidic devices and related methods and systems
US20080163946A1 (en) 2006-12-28 2008-07-10 The Trustees Of California State University Magnetically controlled valve for flow manipulation in polymer microfluidic devices
EP2142279A2 (en) * 2007-04-16 2010-01-13 The General Hospital Corporation d/b/a Massachusetts General Hospital Systems and methods for particle focusing in microchannels
US8691164B2 (en) 2007-04-20 2014-04-08 Celula, Inc. Cell sorting system and methods
US8841135B2 (en) 2007-06-20 2014-09-23 University Of Washington Biochip for high-throughput screening of circulating tumor cells
JP5260919B2 (ja) * 2007-09-05 2013-08-14 浜松ホトニクス株式会社 血液検査装置
JP2011512125A (ja) 2008-02-01 2011-04-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア マイクロ流体画像サイトメトリ
US8546532B2 (en) 2008-04-17 2013-10-01 Declion Pharmaceuticals, Inc. Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
KR101563687B1 (ko) 2008-09-02 2015-11-09 삼성전자주식회사 표적 분자 분리를 위한 미세유동 카트리지, 분리장치, 및 이를 이용한 표적 분자 분리 방법
ES2638861T3 (es) * 2009-04-13 2017-10-24 University Of Washington Método y aparato de detección de partículas raras
US9034658B2 (en) 2009-11-23 2015-05-19 The General Hospital Corporation Microfluidic devices for the capture of biological sample components
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
JP2012237607A (ja) 2011-05-10 2012-12-06 Canon Inc 流体デバイス
CN103732731A (zh) 2011-05-27 2014-04-16 不列颠哥伦比亚大学 用于高通量分析的微流控细胞捕获和分析设备
EP3017308A4 (en) 2013-07-05 2017-04-26 University Of Washington Through Its Center For Commercialization Methods, compositions and systems for microfluidic assays

Also Published As

Publication number Publication date
CA2758382C (en) 2018-01-02
EP2419726A2 (en) 2012-02-22
EP2990795A1 (en) 2016-03-02
US11982678B2 (en) 2024-05-14
JP5734274B2 (ja) 2015-06-17
AU2015234379A1 (en) 2015-10-29
ES2638861T3 (es) 2017-10-24
CA2758382A1 (en) 2010-10-21
AU2010236572A1 (en) 2011-11-10
AU2015234379B2 (en) 2017-06-15
CN102460154B (zh) 2015-10-07
KR101893613B1 (ko) 2018-08-30
CN105242004B (zh) 2018-07-10
JP2012523572A (ja) 2012-10-04
WO2010120818A3 (en) 2011-01-20
US20120129190A1 (en) 2012-05-24
US20190120857A1 (en) 2019-04-25
EP3299812B1 (en) 2020-03-11
JP2017096982A (ja) 2017-06-01
CN105242004A (zh) 2016-01-13
JP6576374B2 (ja) 2019-09-18
CN102460154A (zh) 2012-05-16
EP2419726A4 (en) 2012-10-10
EP3299812A1 (en) 2018-03-28
JP2015083992A (ja) 2015-04-30
JP6182168B2 (ja) 2017-08-16
EP2419726B1 (en) 2015-12-23
WO2010120818A2 (en) 2010-10-21
AU2010236572B2 (en) 2015-07-09
KR20120030362A (ko) 2012-03-28

Similar Documents

Publication Publication Date Title
US11982678B2 (en) Ensemble-decision aliquot ranking
US11808767B2 (en) Methods, compositions and systems for microfluidic assays
JP7344569B2 (ja) 単一の生物学的ナノ粒子分析のための方法および装置
US7993821B2 (en) Methods and apparatus for the isolation and enrichment of circulating tumor cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2419726

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHIU, DANIEL T.

Inventor name: SCHIRO, PEGGY G.

Inventor name: KUO, JASON S.

17P Request for examination filed

Effective date: 20160830

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

17Q First examination report despatched

Effective date: 20160927

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170307

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2419726

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RENTSCH PARTNER AG, CH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 921891

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: BELLERIVESTRASSE 203 POSTFACH, 8034 ZUERICH (CH)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010044755

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2638861

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20171024

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170823

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 921891

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171123

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171223

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171124

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171123

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010044755

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180430

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100413

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170823

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220314

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20220310

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20220328

Year of fee payment: 13

Ref country code: ES

Payment date: 20220506

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230404

Year of fee payment: 14

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230414

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230413

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240314

Year of fee payment: 15

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240321

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230414

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230414